ezetimibe has been researched along with Cardiovascular Diseases in 344 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 50 (14.53) | 29.6817 |
| 2010's | 193 (56.10) | 24.3611 |
| 2020's | 101 (29.36) | 2.80 |
| Authors | Studies |
|---|---|
| Nishikido, T; Ray, KK | 1 |
| Bittner, VA; Brown, TM; Chen, L; Colantonio, LD; Exter, J; Farkouh, ME; Huang, L; Jackson, EA; Levitan, EB; McKinley, EC; Muntner, P; Orroth, KK; Reading, SR; Rosenson, RS; Safford, MM; Woodward, M | 1 |
| Brath, H; Drexel, H; Hemetsberger, M; Hoelzl, R; Ray, KK; Siostrzonek, P; Zweiker, R | 1 |
| Chang, R; Liu, SY; Zhao, LM | 1 |
| Boch, T; Michaeli, DT; Michaeli, JC; Michaeli, T | 2 |
| Cheng, CY; Hsu, CY; Lee, JD; Lee, M; Ovbiagele, B; Wu, YL | 1 |
| Burnett, H; Cichewicz, A; Di Domenico, M; Durand, A; Fahrbach, K; Jindal, R; Reichelt, A; Tarpey, J; Viljoen, A | 1 |
| de Boer, LM; Hof, MH; Hutten, BA; Kastelein, JJP; Stroobants, AK; Wiegman, A | 1 |
| Adachi, H; Hakoshima, M; Katsuyama, H; Yanai, H | 1 |
| Choi, J; Chung, JW; Hong, JH; Jeon, U; Kim, HD; Kim, W; Park, SH; Seong, K; Shin, WY | 1 |
| Huffman, MD; Rodgers, A; Wang, N; Woodward, M | 1 |
| Abushanab, D; Ademi, Z; Al-Badriyeh, D; Bailey, C; Jaam, M; Liew, D; Marquina, C | 1 |
| Jia, Y; Martinez, L; Sanchez, SZ; Wang, X; Xi, X; Xie, W; Zhao, Q | 1 |
| Aertgeerts, B; Bekkering, GET; Delvaux, N; Guyatt, G; Hao, Q; Khan, SU; Li, S; Lone, AN; Riaz, IB; Rodondi, N; Vandvik, PO; Yedlapati, SH | 1 |
| Aertgeerts, B; Agoritsas, T; Al Ansary, L; Assendelft, WJJ; Bekkering, GE; Dawson, A; Delvaux, N; Guyatt, G; Hao, Q; Heen, AF; Jackson, R; Khan, SU; Li, S; Lytvyn, L; Okwen, PM; Ovidiu, MC; Ramaekers, D; Reny, JL; Riaz, IB; Rodondi, N; Siemieniuk, RAC; Spencer, F; Van Driel, M; Vanbrabant, W; Vandvik, PO; Zhao, Q; Zhu, Y | 1 |
| White, HD | 1 |
| Shen, W; Wang, CX; Wu, QH; Yang, PP; Yang, S; Zhang, HZ | 1 |
| Atar, D; Langslet, G; Tonstad, S | 1 |
| Hackam, DG; Hegele, RA | 1 |
| Acín Gericó, MT; Alzueta Istúriz, N; Bartolomé Resano, R; Celaya Lecea, MC; Echeverría Gorriti, A; Fernández González, J; García González, P; Garjón Parra, J; Goñi Zamarbide, O; Sanz Álvarez, L | 1 |
| Calabrò, P; De Ferrari, GM; Filardi, PP; Indolfi, C; Romeo, F | 1 |
| Liuzzo, G; Patrono, C | 1 |
| Ahn, CM; Cho, YH; Choi, D; Heo, JH; Hong, BK; Hong, MK; Hong, SJ; Jang, Y; Kim, BK; Kim, JS; Ko, YG; Lee, SJ; Lee, YJ; Rha, SW; Yun, KH | 1 |
| Kelsey, MD; Newby, LK | 1 |
| Abdul-Rahman, T; Ahmad, S; Awuah, WA; Bandyopadhyay, D; Bukhari, SMA; Capriles, CAA; Corriero, AC; de Andrade, H; Goel, A; Gupta, R; Hajra, A; Herrera, EC; Lawrence, J; Mares, AC; Patel, N; Shah, R; Shaikh, R; Ulusan, S | 1 |
| Ennezat, PV; François, P; Guerbaai, RA; Le Jemtel, TH; Maréchaux, S | 1 |
| Ballantyne, CM; Birtcher, KK; Covington, AM; DePalma, SM; Lloyd-Jones, DM; Minissian, MB; Morris, PB; Orringer, CE; Smith, SC; Waring, AA; Wilkins, JT | 1 |
| Pedicino, D; Volpe, M | 1 |
| Alam, S; Ballantyne, CM; Bhatt, DL; Cannon, CP; de Lemos, JA; Gao, Q; Kosiborod, M; Mues, KE; Rosenson, RS; Shaik, A | 1 |
| Bañeras, J; Bello Mora, MC; Cordero, A; Cortez Quiroga, GA; Fácila, L; García, PB; González-Juanatey, JR; López-Rodríguez, L; Lorenzo, MC; Murillo, JR; Olmo, RF; Pamias, RF; Reyes-Santías, F; Rodríguez-Mañero, M; Romero-Menor, C; Salgado-Barreira, Á; Sánchez-Alvarez, S; Sandin, M; Seijas-Amigo, J; Valle, A | 1 |
| Becker, C; Bilitou, A; Katzmann, JL; Laufs, U | 1 |
| Baum, SJ; Bilitou, A; Gillard, KK; Louie, MJ; McQueen, RB; Nash, B; Ray, KK; Sasiela, WJ; Shah, H | 1 |
| Baum, SJ; Gaudet, D; Gencer, B; Kassahun, H; Knusel, B; Kuder, JF; Lepor, NE; López, JAG; Murphy, SA; O'Donoghue, ML; Ran, X; Rosenson, RS; Sabatine, MS; Stout, E; Wang, H; Wu, Y | 1 |
| Attipoe-Dorcoo, S; Jackson, SL; Loustalot, F; Park, S; Sekkarie, A; Sperling, L; Therrien, NL; Thompson-Paul, AM; Woodruff, RC; Yang, PK | 1 |
| Ahn, CM; Cho, JY; Cho, YH; Choi, D; Hong, MK; Hong, SJ; Im, SW; Jang, Y; Kang, WC; Kim, BK; Kim, JS; Ko, YG; Lee, SJ; Lee, SY; Lee, YH; Lee, YJ; Park, Y; Shin, WY; You, SC; Yun, KH | 1 |
| Calvert, SB; Cziraky, MJ; Eapen, Z; Granger, CB; Haynes, K; Nanna, MG; Nelson, AJ; Pagidipati, NJ; Shambhu, S | 1 |
| Stone, NJ | 1 |
| Sawant, S; Wang, N | 1 |
| Ako, J; Iekushi, K; Majewska, R; Mitani, H; Suzuki, K; Touzeni, S; Yamashita, S | 1 |
| Cha, JJ; Cho, JM; Hong, SJ; Joo, HJ; Kim, JH; Kim, JS; Kim, SY; Lee, CW; Lee, JY; Lee, K; Lee, PH; Lee, SW; Lim, DS; Lim, S; Lim, SY; Moon, JY; Na, JO; Park, JH; Park, JS; Yu, CW | 1 |
| Ahn, CM; Choi, D; Choi, HH; Choi, YJ; Heo, JH; Hong, MK; Hong, SJ; Hur, SH; Jang, Y; Kim, BK; Kim, JH; Kim, JS; Kim, KJ; Ko, YG; Lee, JH; Lee, SH; Lee, SJ; Lee, YJ; Park, KH | 1 |
| Boersma, E; Bogsrud, MP; Hamkour, S; Holven, KB; Imholz, B; Johansen, AK; Koopal, C; Louters, L; Retterstøl, K; Roeters van Lennep, JE; Schreuder, MM; Siegers, KE; van de Ree, MA; Visseren, FLJ | 1 |
| Chang, Y; Eom, S; Kim, M; Song, TJ | 1 |
| Ford, GA; Hamed, J; Kearney, M; Metcalfe, AM; Newton, JL; Williams, H | 1 |
| Hong, YA; Kim, DW; Lee, K; Lee, M; Myong, JP; Park, MW | 1 |
| Allison, J; Mounsey, A; Reddy, V | 1 |
| Albers, S; Boch, T; Michaeli, DT; Michaeli, JC; Michaeli, T | 1 |
| Di Costanzo, A; Esposito, G; Indolfi, C; Sorrentino, S; Spaccarotella, CAM | 1 |
| Aker, A; Naoum, I; Saliba, W; Zafrir, B | 1 |
| Gillard, KK; Gupta, A; Israel, MK; Kolkailah, AA; Navar, AM; Peterson, ED; Wang, Y | 1 |
| Ahn, CM; Cha, JJ; Cho, YH; Choi, D; Choi, S; Choi, WG; Hong, MK; Hong, SJ; Jang, Y; Jeong, JO; Kim, BK; Kim, JS; Ko, YG; Lee, SJ; Lee, WS; Lee, YJ; Park, W; Yoon, CH | 1 |
| Landmesser, U; Sinning, D | 1 |
| Aertgeerts, B; Du, H; Gan, L; Hao, Q; Hu, M; Li, S; Xiang, Y | 1 |
| Allan, GM; Braschi, É; Dugré, N; Falk, J; Froentjes, L; Garrison, SR; Kirkwood, JEM; Kolber, MR; Korownyk, CS; Lindblad, AJ; McCormack, JP; Moe, SS; Paige, A; Perry, D; Potter, J; Thomas, BS; Ton, J; Weresch, J; Young, J | 1 |
| Iihara, N; Nakatsuma, A; Sato, T; Senda, S; Tomida, J; Yoshida, T | 1 |
| Kim, HS; Kim, NH; Kim, SG; Kim, SS; Ko, SH; Lee, BK; Lee, I; Lee, JH; Moon, JS; Park, IR; Won, KC | 1 |
| Leong, D; Wu, PE | 1 |
| Kang, LN; Lan, RF; Wang, L; Xu, B; Xu, W; Zhang, XL; Zhang, XW | 1 |
| Blazing, MA; Bohula, EA; Braunwald, E; Califf, RM; Cannon, CP; Giugliano, RP; Jarolim, P; Morrow, DA; Murphy, SA; Park, JG; Qamar, A | 1 |
| Badimón, L; Civeira, F; Guijarro, C; López-Miranda, J; Masana, L; Millán, J; Mostaza, JM; Pedro-Botet, J; Pintó, X; Valdivielso, P | 1 |
| Hu, H; Lin, S; Liu, T; Xu, H; Yang, J; Yao, Q; Yu, Y; Zhu, Y | 1 |
| Abtan, J; Amarenco, P; Béjot, Y; Bruckert, E; Cabrejo, L; Cha, JK; Charles, H; Ducrocq, G; Giroud, M; Guidoux, C; Hobeanu, C; Kim, JS; Kim, YJ; Labreuche, J; Lapergue, B; Lavallée, PC; Lee, BC; Lee, KB; Leys, D; Mahagne, MH; Meseguer, E; Nighoghossian, N; Pico, F; Samson, Y; Sibon, I; Steg, PG; Sung, SM; Touboul, PJ; Touzé, E; Varenne, O; Vicaut, É; Yelles, N | 1 |
| Biagini, S; Bigazzi, F; Fogliaro, MP; Luciani, R; Pianelli, M; Pino, BD; Ripoli, A; Sampietro, T; Sbrana, F; Surdo, GL; Volpi, E | 1 |
| Ambrosio, G; Armstrong, PW; De Ferrari, GM; Green, JB; Holman, RR; Leonardi, S; Peterson, ED; Stevens, SR; Wamil, M | 1 |
| Antonazzo, IC; Biagini, S; Bigazzi, F; Calabria, S; Dondi, L; Gini, R; Maggioni, AP; Martini, N; Pedrini, A; Piccinni, C; Pino, BD; Roberto, G; Ronconi, G; Sampietro, T; Sbrana, F; Surdo, GL; Volpi, E | 1 |
| Pedro-Botet, J; Pintó, X | 1 |
| Kaszyńska, M; Żebrowski, P | 1 |
| Bilato, C; Coats, AJS; Drexel, H; Mollace, V; Perrone Filardi, P; Rosano, GMC; Spoletini, I | 1 |
| Almeida, JT; Esteves, AL; Martins, F; Palma, I | 1 |
| Ahmed, ST; Akeroyd, JM; Ballantyne, CM; Dixon, DL; Gluckman, TJ; Jia, X; Nambi, V; Petersen, LA; Ramsey, DJ; Rifai, MA; Stone, NJ; Virani, SS | 1 |
| Brandts, J; Ray, KK | 1 |
| Češka, R | 1 |
| Hu, M; Li, N; Li, S; Tian, H; Xiao, Z; Yang, H; Zhou, Y | 1 |
| Blom, DJ; Bouharati, C; Chilton, R; Ebrahim, IO; Karamchand, S; Leisegang, RF; Musa, MG; Naidoo, P; Raal, FJ; Rambiritch, V; Ranjith, N; Shunmoogam, N; Tonder, AV | 1 |
| Lütjohann, D; Sijbrands, E; Weingärtner, O | 1 |
| Kuwabara, M; Ouchi, Y; Saikawa, T; Sasaki, J | 1 |
| Bae, GH; Jung, J; Kang, M; Kim, SW; Lee, DH | 1 |
| Chen, YM; Chiang, WC; Chou, YH; Chu, TS; Lai, TS; Lin, SL; Lin, YC; Tu, YK; Wu, HY | 1 |
| Fratter, A; Lenti, S; Mazza, A; Nicoletti, M; Pellizzato, M; Rigatelli, G; Torin, G | 1 |
| Arashi, H; Hagiwara, N; Nakazawa, M; Ogawa, H; Yamaguchi, J | 1 |
| Paquot, N; Wallemacq, C | 1 |
| Berklein, F; Feng, X; Habib, M; Lin, PJ; Rane, PB | 1 |
| Adam, S; Durrington, PN; France, M; Ho, JH; Iqbal, Z; Soran, H | 1 |
| Colivicchi, F; Corsini, A; De Luca, L; Uguccioni, M | 1 |
| Khan, SA; Naz, A; Qamar Masood, M; Shah, R | 1 |
| Carter, JL; Casas, JP; Hingorani, AD; Overington, JP; Pearce, LS; Schmidt, AF; Wilkins, JT | 1 |
| Genkel, VV; Salashenko, AO; Shaposhnik, II | 1 |
| Braunwald, E; Cannon, CP; Gencer, B; Giugliano, RP; Im, K; Keech, A; Marston, NA; Sabatine, MS; Sever, P | 1 |
| Chang, D; Cheng, Y; Su, X | 1 |
| Blumenthal, RS; Dhindsa, DS; Karagiannis, AD; Mehta, A; Orringer, CE; Sperling, LS; Stone, NJ; Virani, SS | 1 |
| Casula, M; Catapano, AL; Pirillo, A; Tokgözoğlu, L | 1 |
| Alkhouli, M; Blaha, MJ; Blumenthal, RS; Kalra, A; Khan, MS; Khan, MU; Khan, MZ; Khan, SU; Michos, ED; Rashid, M; Virani, SS | 1 |
| Lindsley, J | 1 |
| Wiklund, O | 1 |
| Anderson, TJ; Barry, AR; Couture, P; Dayan, N; Francis, GA; Genest, J; Grégoire, J; Grover, SA; Gupta, M; Hegele, RA; Lau, D; Leiter, LA; Leung, AA; Lonn, E; Mancini, GBJ; Manjoo, P; McPherson, R; Ngui, D; Pearson, GJ; Piché, ME; Poirier, P; Sievenpiper, J; Stone, J; Thanassoulis, G; Ward, R; Wray, W | 1 |
| Diaconu, CC; Furtunescu, F; Iorga, RA; Katsiki, N; Rizzo, M; Stoian, AP | 1 |
| Guo, X; Hu, Z; Ma, W; Ma, Y | 1 |
| Pottle, A; Quoraishi, SH; Reynolds, TM | 1 |
| Cui, Y; Jin, S; Li, Y; Nie, X; Yuan, J; Zhao, L | 1 |
| Ademi, Z; Ilomaki, J; Liew, D; Lybrand, S; Marquina Hernandez, C; Ofori-Asenso, R; Owen, A; Petrova, M; Talic, S; Thomson, D; Zomer, E | 1 |
| Andretta, M; Avogaro, A; Degli Esposti, L; Fadini, GP; Morieri, ML; Perrone, V; Plebani, M; Veronesi, C; Vigili de Kreutzenberg, S | 1 |
| Lloyd-Jones, DM; Wilkins, JT | 1 |
| O'Sullivan, CSE; Tejani, AM | 1 |
| Korman, M; Wisløff, T | 1 |
| Casas, JP; Hingorani, AD; Overington, JP; Pearce, LS; Schmidt, AF; Wilkins, JT | 1 |
| Jaffa, FM; Johnson, E; Kalyani, RR; Shubrook, JH; Skolnik, N | 1 |
| Grant, PJ | 1 |
| Kampangkaew, J; Nambi, V; Pickett, S | 1 |
| Humphries, KH; Mancini, GBJ | 1 |
| Choby, B | 1 |
| Civeira, F; Ibarretxe, D; Lamiquiz-Moneo, I; Masana, L; Ortega, E; Pedro-Botet, J; Pérez-Calahorra, S; Plana, N; Suárez-Tembra, M; Valdivielso, P | 1 |
| Bellia, A; Cricelli, C; Cricelli, I; Della-Morte, D; Guglielmi, V; Lapi, F; Lauro, D; Medea, G; Parretti, D; Pecchioli, S; Sbraccia, P | 1 |
| Cannon, CP; Genest, J; Gupta, M; Mancini, GBJ; Raggi, P; Ray, KK; Santos, RD; Tsigoulis, M; Watts, GF | 1 |
| Flugelman, MY; Halon, DA; Jubran, A; Lavie, G; Shapira, C; Zafrir, B | 1 |
| Dent, R; Descamps, OS; Fraass, U; Gouni-Berthold, I; März, W | 1 |
| Lüscher, TF | 2 |
| Wójcik, C | 1 |
| Koskinas, KC; Mach, F; Mavridis, D; Piccolo, R; Räber, L; Siontis, GCM; Windecker, S | 1 |
| Beaubrun, A; Davis, K; Fox, KM; Inomata, H; Kajinami, K; Meyers, J; Nagar, SP; Qian, Y; Rane, PP | 1 |
| Cervelli, N; Ferri, C; Tocci, G | 1 |
| Battaggia, A; Donzelli, A; Scalisi, A | 1 |
| Shang, H; Wu, H; Wu, J | 1 |
| Jacoby, D; Russell, C; Sheth, S | 1 |
| Reynolds, TM; Viljoen, A; Wierzbicki, AS | 1 |
| Ahmed, H; Bin Riaz, I; Kaluski, E; Khan, SU; Krasuski, R; Nasir, F; Rahman, H; Riaz, H; Sattur, S; Talluri, S | 1 |
| Carter, RE; Wang, Z | 1 |
| Bin Abdulhak, AA; Robinson, JG | 1 |
| Andreotti, F; Bliden, K; Gurbel, PA; Kolodziejczak, M; Kowalewski, M; Kubica, J; Navarese, EP; Raggi, P; Robinson, JG; Tantry, U | 1 |
| Cannon, CP; Lee, S | 1 |
| Bujas-Bobanovic, M; Ganda, OP; Koren, A; Leiter, LA; Letierce, A; Mandel, J; Plutzky, J; Sanganalmath, SK | 1 |
| Blazing, M; Cannon, CP; Chung, RT; Corey, KE; Giugliano, RP; O'Donoghue, ML; Park, JG; Simon, TG | 1 |
| Packard, CJ | 1 |
| Hsiung, JT; Kleine, CE; Moradi, H; Park, C; Soohoo, M; Streja, DA; Streja, E | 1 |
| Robinson, JG; Watson, KE | 1 |
| Bálinth, K; Bugáňová, I; Fábryová, Ľ; Kadurová, M; Klabník, A; Kozárová, M; Rašlová, K; Sirotiaková, J; Vohnout, B | 1 |
| Barron, JK; Blom, DJ; Brice, BC; Huijgen, R; Marais, AD; van Delden, XM; Wolmarans, KH | 1 |
| Blaha, V; Freiberger, T; Kyselak, O; Maskova, J; Raslová, K; Satny, M; Soska, V; Urbanek, R; Vaclova, M; Vohnout, B; Vrablik, M | 1 |
| Abdullaeva, G; Alieva, R; Hoshimov, S; Kurbanov, R; Nagay, A; Nizamov, U; Shek, A | 1 |
| Adam, S; Durrington, PN; Soran, H | 1 |
| Ambegaonkar, B; Baxter, CA; Davies, G; Jansen, J; Lorenzi, M; Zoratti, MJ | 1 |
| Rana, JS; Warraich, HJ | 1 |
| Bessac, L; Cannon, CP; Davidson, MH; Eckel, RH; Ginsberg, HN; Lee, LV; Letierce, A; Pordy, R; Ray, KK; Vallejo-Vaz, AJ | 1 |
| Bailey, AL; Beam, C; Birtcher, KK; Blumenthal, RS; Braun, LT; de Ferranti, S; Faiella-Tommasino, J; Forman, DE; Goldberg, R; Grundy, SM; Heidenreich, PA; Hlatky, MA; Jones, DW; Lloyd-Jones, D; Lopez-Pajares, N; Ndumele, CE; Orringer, CE; Peralta, CA; Saseen, JJ; Smith, SC; Sperling, L; Stone, NJ; Virani, SS; Yeboah, J | 2 |
| Liu, F; Shu, M; Tang, M; Wu, X; Xia, P; Zhan, S | 1 |
| Bärlocher, A; Bilz, S; Brändle, M; Gerth, Y; Korte, W; Müller, P; Rickli, H; Schöb, M | 1 |
| Brownrigg, J; Catterick, D; Danese, MD; Gleeson, M; Khunti, K; Kondapally Seshasai, SR; Kutikova, L; Ray, KK; Sorio-Vilela, F | 1 |
| Athyros, V; Karagiannis, A; Katsiki, N; Reklou, A | 1 |
| Arbel, R; Azuri, J; Hammerman, A | 1 |
| Cannon, CP; Khan, I; Klimchak, AC; Reynolds, MR; Rosenson, RS; Sanchez, RJ; Sasiela, WJ | 1 |
| Chan, P; Liu, Z; Ma, YB; Tomlinson, B; Zhang, Y | 1 |
| Jin, MM; Li, J; Li, N; Liu, HZ; Miao, XY; Sun, BR; Tian, H; Yan, ST | 1 |
| Blumenthal, RS; Chuzi, S; Grundy, SM; Lloyd-Jones, DM; Pfenniger, A; Smith, SC; Stone, NJ; Virani, SS | 1 |
| Grundy, SM; Stone, NJ | 1 |
| Baigent, C; Collins, R; Emberson, J; Gray, A; Haynes, R; Herrington, W; Kent, S; Landray, MJ; Mihaylova, B; Reith, C; Schlackow, I | 1 |
| Simons, LA | 1 |
| Galyavich, AM; Gurevich, VS; Kaminnyi, AI; Kashtalap, VV; Kobalava, JD; Mareev, VY; Shaposhnik, II; Susekov, AV | 1 |
| Erickson, KF; Walther, CP | 1 |
| Ademi, Z; Chaiyakunapruk, N; Chaiyasothi, T; Kongpakwattana, K; Liew, D; Nathisuwan, S; Zomer, E | 1 |
| Khan, SU; Michos, ED | 1 |
| Feingold, KR | 1 |
| Banach, M; Katsiki, N; Mikhailidis, DP | 1 |
| Ballantyne, CM; Bays, HE; Catapano, AL; Goldberg, AC; Laufs, U; Leiter, LA; MacDougall, D; Ray, KK; Stroes, ES; Zhao, X | 1 |
| Brath, H; Kästenbauer, T; Toplak, H; Wascher, TC | 1 |
| Aguirre, AC; Amaral, JB; Barbosa, SP; Bianco, HT; Fonseca, FA; França, CN; Izar, MC; Lins, LC; Matos, LN; Santana, JM | 1 |
| Couture, P; Lamarche, B | 1 |
| Cabré, A; Masana, L; Plana, N | 1 |
| Shoji, T | 1 |
| Alexopoulos, D; Davlouros, P; Perperis, A; Siahos, S; Xanthopoulou, I; Zaharioglou, E | 1 |
| Braamskamp, MJ; Hutten, BA; Kastelein, JJ; Wiegman, A | 1 |
| Baumgartner, I; März, W; Silbernagel, G; Wanner, C | 1 |
| Hamai, J; Kamiko, K; Kawasaki, S; Kondo, Y; Nezu, U; Shigematsu, E; Takahashi, M; Takano, T; Terauchi, Y; Yamada, M; Yamakawa, T; Yamazaki, S; Yoshii, T | 1 |
| Iwasaka, T; Jo, F; Kubo, R; Kusabe, M; Morimoto, S; Morita, T; Nakahigashi, M; Nakano, C; Okuno, Y; Seo, M; Shiojima, I; Someya, K; Takahashi, N; Toyoda, N; Ueda, H | 1 |
| Aguirre, AC; Barbosa, SP; Bianco, HT; do Amaral, JB; Fonseca, FA; França, CN; Izar, MC; Lins, LC; Matos, LN | 1 |
| Cavasin, MA; Chonchol, M; Demos-Davies, KM; Jablonski, K; Keenan, AL; Kendrick, J; Levi, M; Masuda, M; Masuda, R; McKinsey, TA; Miyazaki, M; Miyazaki-Anzai, S; Saunders, SJ | 1 |
| Gong, YZ; Li, GY; Li, XL; Liao, DF; Luo, HD; Qin, L; Xie, XJ; Yang, YB; Yang, YX; Zheng, XL | 1 |
| Blazing, MA; Braunwald, E; Califf, RM; Cannon, CP; Giugliano, RP; McCagg, A; Musliner, TA; Reist, C; Tershakovec, AM; White, JA | 1 |
| Brudi, P; Catapano, AL; Farnier, M; Foody, JM; Tershakovec, AM; Tomassini, JE; Toth, PP | 1 |
| Barkas, F; Elisaf, M; Kostapanos, MS; Liberopoulos, E; Mikhailidis, DP; Milionis, H | 1 |
| Amadio, A; Harbin, M; Tejani, A | 1 |
| Hegele, RA; McPherson, R | 1 |
| Ferenci, T; Simonyi, G | 1 |
| Ambegaonkar, BM; Cao, X; Ejzykowicz, F; Mavros, P; Ramey, DR; Sajjan, S; Tunceli, K | 1 |
| Blom, D; Cannon, CP; Cariou, B; Chaudhari, U; Colhoun, HM; Lorenzato, C; McKenney, JM; Pordy, R | 1 |
| Allan, GM; Turgeon, RD; Zarnke, KB | 1 |
| Civeira, F; Masana, L; Pedro-Botet, J | 1 |
| Viljoen, A; Wierzbicki, AS | 2 |
| Packard, C; Stezhka, T | 1 |
| Catapano, AL; Pirillo, A | 1 |
| Battaggia, A; Donzelli, A; Font, M; Galvano, A; Molteni, D | 1 |
| Deckers, JW; Simoons, ML | 2 |
| Poli, A | 1 |
| Cífková, R; Krajčoviechová, A | 1 |
| Bays, H; Donahue, S; Gaudet, D; Gouni-Berthold, I; Hanotin, C; Robinson, J; Ruiz, JL; Watts, GF; Weiss, R; Zhao, J | 1 |
| Blazing, MA; Bohula, EA; Braunwald, E; Califf, RM; Cannon, CP; Darius, H; De Ferrari, GM; De Lucca, P; Giugliano, RP; Im, K; Jukema, JW; Lewis, BS; McCagg, A; Musliner, TA; Ophuis, TO; Reist, C; Ruzyllo, W; Tershakovec, AM; Theroux, P; White, JA; Wiviott, SD | 1 |
| Catapano, AL; Ference, BA | 1 |
| Durrington, PN; Schofield, JD; Soran, H | 1 |
| Hayashi, T; Ijiri, Y; Kato, R; Kitaura, Y; Miyamura, M; Nishioka, S; Nomura, A; Okada, Y; Ukimura, A | 1 |
| Makris, T; Michalopoulou, H; Skalis, G; Thomopoulos, C; Tsioufis, C | 1 |
| De Ferrari, GM; Perrone-Filardi, P; Rosano, GM; Savarese, G | 1 |
| Ennezat, PV; Guerbaai, RA; Nicot, P | 1 |
| Graversen, CB; Larsen, ML; Schmidt, EB | 1 |
| Blazing, MA; Bohula, EA; Braunwald, E; Cannon, CP; Giugliano, RP; Murphy, SA; Tershakovec, AM; White, JA; Zhou, J | 1 |
| Almquist, T; Hjemdahl, P; Jacobson, SH; Mobarrez, F; Wallén, H | 1 |
| Knight, M; Sando, KR | 1 |
| Davidson, M; Smith, BA; Wright, C | 1 |
| Ferguson, LD; Logue, J | 1 |
| Banach, M; Mikhailidis, DP; Serban, MC | 1 |
| Baigent, C; Cass, A; Collins, R; Craig, J; Emberson, J; Gray, A; Haynes, R; Herrington, W; Kent, S; Landray, MJ; Lozano-Kühne, J; Mihaylova, B; Reith, C; Schlackow, I | 1 |
| Averna, M; Colhoun, HM; Donahue, S; Du, Y; Farnier, M; Hanotin, C; Jones, P; Severance, R; Steinhagen-Thiessen, E | 1 |
| Lancellotti, P; Pierard, LA; Scheen, AJ | 1 |
| Agarwala, A; Kajani, Z; Miedema, MD; Virani, SS | 1 |
| Goldstein, MR; Mascitelli, L | 2 |
| Hayward, RA; Hofer, TP; Sussman, JB | 1 |
| Perrone-Filardi, P; Savarese, G | 1 |
| Battaggia, A; Donzelli, A | 1 |
| Catapano, AL; Norata, GD; Pirillo, A | 1 |
| Scheen, AJ | 2 |
| Connolly, JG; Gagne, JJ | 1 |
| Farnier, M; Foody, JM; Tershakovec, AM; Tomassini, JE; Toth, PP | 1 |
| Albers, JJ; Fleg, JL; Marcovina, SM; O'Brien, KD; Slee, A | 1 |
| Blazing, MA; Braunwald, E; Cannon, CP; Giugliano, RP; Murphy, SA; Tershakovec, AM | 1 |
| Krähenbühl, S; Pavik-Mezzour, I; von Eckardstein, A | 1 |
| Karádi, I; Paragh, G | 1 |
| Alberto, D; Alessandro, B | 1 |
| Groves, C; Ramachandran, S; Shetty, C; Strange, RC; Waldron, J | 1 |
| Bibbins-Domingo, K; Coxson, PG; Guzman, D; Kazi, DS; Moran, AE; Ollendorf, DA; Pearson, SD; Penko, J; Tice, JA | 1 |
| Barrett, PH; Burnett, JR; Chan, DC; Mori, TA; Pang, J; Sullivan, DR; van Bockxmeer, FM; Watts, GF | 1 |
| Chung, RT; Corey, KE; Giugliano, R; Simon, TG | 1 |
| Araujo, MB; Pacce, MS | 1 |
| Bessac, L; Cannon, CP; Davidson, MH; Eckel, RH; Ginsberg, HN; Minini, P; Pordy, R; Ray, KK | 1 |
| Collins, PD; Sattar, N | 1 |
| Araya, FI; Grassi, B | 1 |
| Ahn, Y; Bae, JH; Cho, HJ; Cho, JM; Cho, KI; Cho, YK; Chun, WJ; Jang, Y; Jin, DK; Jin, HY; Kim, BJ; Kim, BS; Kim, MA; Kim, SY; Koh, KK; Lee, B; Lee, BK; Lee, HC; Lee, J; Lee, N; Lee, SC; Lee, SG; Lee, SH; Oh, SJ; Park, C; Park, CG; Park, JI; Park, JS; Park, WJ; Ryu, JK; Suh, J; Yang, YJ | 1 |
| Csécsei, P; Karádi, Z; Lovadi, E; Lovig, C; Szapáry, L | 1 |
| Agodoa, L; Baigent, C; Emberson, J; Haynes, R; Herrington, W; Judge, PK; Landray, MJ; Lewington, S; Mafham, M; Reith, CA; Staplin, N; Tomson, C; Walker, R; Wheeler, DC; Wiecek, A | 1 |
| DiNicolantonio, JJ; Lavie, CJ; O'Keefe, JH | 1 |
| Agarwal, A; Alexander, PE; Bhatnagar, N; El Dib, R; Fei, Y; Gomaa, H; Guyatt, GH; Morgan, RL; Nunnally, ME; Siemieniuk, RAC; Spencer, FA; Vandvik, PO; Zhang, Y | 1 |
| Duarte, F; Ginsberg, HN; Khavandi, M; Reyes-Soffer, G | 1 |
| Basurto, L; Hernández-Valencia, M; Manuel-Apolinar, L; Saucedo, R; Zárate, A | 1 |
| Cziraky, MJ; Fox, KM; Gandra, SR; Paoli, CJ; Punekar, RS; Richhariya, A; Toth, PP | 1 |
| Catapano, AL; Grigore, L; Norata, GD | 1 |
| Alemao, E; Davies, GM; Hildebrandt, P; Keiding, H | 1 |
| Kohalmy, K; Monostory, K; Pascussi, JM; Rozman, D; Sárváry, E | 1 |
| Boman, K; Brudi, P; Chambers, JB; Egstrup, K; Gerdts, E; Gohlke-Bärwolf, C; Holme, I; Kesäniemi, YA; Malbecq, W; Nienaber, CA; Pedersen, TR; Ray, S; Rossebø, AB; Skjaerpe, T; Wachtell, K; Willenheimer, R | 1 |
| Ara, R; Chilcott, J; Duenas, A; Durrington, P; Paisley, S; Pandor, A; Tumur, I; Wilkinson, A; Williams, R | 1 |
| Díaz Gómez, JM | 1 |
| Burgos, D; Cabello, M; González Molina, M; Gutiérrez, C; Gutiérrez, E; López, V; Sola, E | 1 |
| Guthrie, R | 1 |
| Hamilton, P | 1 |
| Hughes, S | 1 |
| Ara, R; Chilcott, J; Duenas, A; Durrington, P; Paisley, S; Pandor, A; Rees, A; Tumur, I; Wilkinson, A; Williams, R | 1 |
| Davidson, MH; Dembowski, E | 1 |
| Avis, HJ; Hutten, BA; Kastelein, JJ; Vissers, MN; Wijburg, FA | 1 |
| Stein, EA | 1 |
| Al Badarin, FJ; Kopecky, SL; Kullo, IJ; Thomas, RJ | 1 |
| Blazing, MA; Califf, RM; Harrington, RA | 1 |
| Abbink, EJ; Huijgen, R; Imholz, BP; Kastelein, JJ; Liem, AH; Pijlman, AH; Stalenhoef, AF; Verhagen, SN; Visseren, FL | 1 |
| Visseren, FL; Westerink, J | 1 |
| Bass, A; Hinderliter, AL; Lee, CR | 1 |
| Abel, T; Dinya, E; Eldin, MG; Fehér, J; Kovács, A | 1 |
| Charland, SL; Malone, DC | 1 |
| Calvert, NW; Demott, K; Humphries, SE; Minhas, R; Neil, HA; Nherera, L; Thorogood, M | 1 |
| Mitka, M | 1 |
| Rosenson, RS | 1 |
| Radermecker, RP; Scheen, AJ | 1 |
| Rodondi, N | 1 |
| Brosteaux, C; Buclin, T; Kuntzer, T; Rodondi, N; Ruiz, J | 1 |
| Allgar, V; Chipperfield, R; Gaunt, R; Harvey, P; McCormack, T; Robinson, P | 1 |
| Masuda, D; Nakagawa-Toyama, Y; Nishida, M; Ohama, T; Tsubakio-Yamamoto, K; Yamashita, S | 1 |
| Howard, WJ | 1 |
| Ahmed, MH; Byrne, CD | 1 |
| Ban, N; Endo, K; Kawana, H; Miyashita, Y; Nagayama, D; Nagumo, A; Ohira, M; Oyama, T; Saiki, A; Shirai, K; Yamaguchi, T | 1 |
| Drazen, JM; Wood, AJ | 1 |
| Dong, YF; Fukuda, M; Kataoka, K; Kim-Mitsuyama, S; Nakamura, T; Nako, H; Ogawa, H; Tokutomi, Y; Yasuda, O | 1 |
| Gensini, GF; Hanson, ME; Le Grazie, C; Rotella, CM; Zaninelli, A | 1 |
| Ishibashi, S; Kotani, K; Miyamoto, M; Nagasaka, S; Okada, K; Osuga, J; Yagyu, H | 1 |
| Olsson, AG | 1 |
| Erdmann, E | 1 |
| Ikeda, S; Maemura, K | 1 |
| Yamaoka-Tojo, M | 1 |
| Ahmed, MH; Khalil, AA | 1 |
| Jacobson, TA | 1 |
| Goldstein, MR; Mascitelli, L; Pezzetta, F | 1 |
| Doggrell, SA | 2 |
| Davis, HR; Lowe, RS; Neff, DR | 1 |
| Cardoso, SM; da Silva, PM | 1 |
| Mann, MK | 1 |
| Barnes, JP; Friedman, HS; Rajagopalan, S; Roseman, H | 1 |
| Elis, A; Stein, EA; Zhou, R | 1 |
| Boyden, T; Khanderia, U; Regal, RE; Rubenfire, M | 1 |
| Alonso, R; Badimón, L; Barba, A; Díaz, JL; Fuentes, F; Guallar, E; Irigoyen, L; López-Miranda, J; Mata, N; Mata, P; Muñiz, O; Ordovas, JM; Padró, T; Perez-Jiménez, F; Piedecausa, M; Sanchez, JF; Vidal, JI | 1 |
| Jardine, AG; Stevens, KK | 1 |
| Agodoa, L; Armitage, J; Baigent, C; Baxter, A; Bray, C; Cass, A; Chen, Y; Chen, Z; Collins, R; Craig, J; Dasgupta, T; de Zeeuw, D; Emberson, J; Feldt-Rasmussen, B; Fellström, B; Gaziano, M; Grimm, R; Grobbee, D; Grönhagen-Riska, C; Herrington, W; Hill, M; Holdaas, H; Hooi, LS; Jiang, L; Kasiske, B; Knott, C; Krairittichai, U; Krane, V; Landray, MJ; Levin, A; Lewis, D; Mafham, M; Majoni, W; Massy, ZA; Neal, B; Ophascharoensuk, V; Parish, S; Pedersen, T; Reith, C; Simpson, D; Sleight, P; Tesar, V; Tobert, J; Tomson, C; Walker, R; Wallendszus, K; Wanner, C; Wheeler, DC; Wiecek, A; Young, A | 1 |
| Boman, K; Devereux, RB; Egstrup, K; Gohlke-Baerwolf, C; Greve, AM; Kesäniemi, YA; Køber, L; Nienaber, C; Ray, S; Rossebø, AB; Wachtell, K; Willenheimer, R | 1 |
| Császár, A; Farnier, M; Retterstøl, K; Steinmetz, A | 1 |
| Civeira, F; Dan, AG; De Tilleghem, Cle B; Hanson, ME; Hing Ling, PK; Massaad, R; Milardo, C; Triscari, J | 1 |
| Prasad, V; Vandross, A | 1 |
| Elisaf, MS; Florentin, M; Liamis, G; Liberopoulos, EN; Moutzouri, E | 1 |
| Arca, M; Budal, S; Degli Esposti, E; Degli Esposti, L; Sangiorgi, D; Vigna, GB | 1 |
| Banach, M; Davidson, M; Mikhailidis, DP; Nicholls, SJ; Otocka-Kmiecik, A; Rysz, J | 1 |
| Boman, K; Cramariuc, D; Gerdts, E; Gohlke-Bärwolf, C; Lønnebakken, MT; Rieck, ÅE; Rossebø, AB; Staal, EM | 1 |
| Colotto, M; Durante, C; Renzi, A | 1 |
| Bestehorn, K; Gitt, AK; Jannowitz, C; Karmann, B; Pittrow, D; Schaefer, JR; Sonntag, F; Weizel, A | 1 |
| Keane, WF; Neff, DR; Tomassini, JE | 1 |
| Ambrosi, P; Andréjak, M; Gayet, JL | 1 |
| Owen, OG | 1 |
| Schunack, W | 1 |
| Krone, W; Müller-Wieland, D | 1 |
| Davidson, MH; Toth, PP | 1 |
| Mosca, L | 1 |
| Füessl, HS | 1 |
| Balbisi, EA | 1 |
| Davidson, MH; Robinson, JG | 1 |
| Czuriga, I; Edes, I | 1 |
| Francis, GA; Gilchrist, DM; Gyenes, GT; Opgenorth, A; Pearson, GJ; Romney, JS | 1 |
| Cicero, AF; Derosa, G; Salvadeo, S | 1 |
| Farmer, JA; Gotto, AM | 1 |
| Athyros, VG; Elisaf, M; Gazi, IF; Liberopoulos, EN; Mikhailidis, DP | 1 |
| Backes, JM; Gibson, CA; Howard, PA | 1 |
| Ballantyne, CM; Duffield, E; Eber, B; Moccetti, T; Sosef, F; Vogt, A; Weiss, R | 1 |
| Barnett, D; Charles, Z; Pugh, E | 1 |
| Armitage, J | 1 |
| Barho, C; Bode, C; Darius, H; Hildemann, S; Karmann, B; Pittrow, D | 1 |
| Bruckert, E | 1 |
| Malik, P | 1 |
134 review(s) available for ezetimibe and Cardiovascular Diseases
| Article | Year |
|---|---|
The power of lipid registries for cardiovascular disease prevention.
Topics: Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol, LDL; Dyslipidemias; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Registries; Treatment Outcome | 2021 |
Association Between Intensity of Low-Density Lipoprotein Cholesterol Reduction With Statin-Based Therapies and Secondary Stroke Prevention: A Meta-analysis of Randomized Clinical Trials.
Topics: Aged; Anticholesteremic Agents; Atherosclerosis; Cardiovascular Diseases; Cholesterol, LDL; Ezetimibe; Hemorrhagic Stroke; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Randomized Controlled Trials as Topic; Stroke | 2022 |
Comparative efficacy of non-statin lipid-lowering therapies in patients with hypercholesterolemia at increased cardiovascular risk: a network meta-analysis.
Topics: Anticholesteremic Agents; Bayes Theorem; Cardiovascular Diseases; Cholesterol; Cholesterol, LDL; Ezetimibe; Heart Disease Risk Factors; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hyperlipidemias; Network Meta-Analysis; Risk Factors; Treatment Outcome | 2022 |
Molecular Biological and Clinical Understanding of the Statin Residual Cardiovascular Disease Risk and Peroxisome Proliferator-Activated Receptor Alpha Agonists and Ezetimibe for Its Treatment.
Topics: Atherosclerosis; Cardiovascular Diseases; Cholesterol; Cholesterol, HDL; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin Resistance; Lipoproteins; PPAR alpha; Randomized Controlled Trials as Topic; Triglycerides | 2022 |
Compounding Benefits of Cholesterol-Lowering Therapy for the Reduction of Major Cardiovascular Events: Systematic Review and Meta-Analysis.
Topics: Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol; Cholesterol, LDL; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Risk Factors | 2022 |
A Systematic Review of Cost-Effectiveness of Non-Statin Lipid-Lowering Drugs for Primary and Secondary Prevention of Cardiovascular Disease in Patients with Type 2 Diabetes Mellitus.
Topics: Anticholesteremic Agents; Cardiovascular Diseases; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Ezetimibe; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Niacin; Proprotein Convertases; Secondary Prevention; Subtilisins | 2023 |
PCSK9 inhibitors and ezetimibe with or without statin therapy for cardiovascular risk reduction: a systematic review and network meta-analysis.
Topics: Adult; Anticholesteremic Agents; Cardiovascular Diseases; Ezetimibe; Heart Disease Risk Factors; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Network Meta-Analysis; PCSK9 Inhibitors; Proprotein Convertase 9; Risk Factors; Stroke | 2022 |
PCSK9 inhibitors and ezetimibe for the reduction of cardiovascular events: a clinical practice guideline with risk-stratified recommendations.
Topics: Adult; Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol, LDL; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; PCSK9 Inhibitors; Proprotein Convertase 9; Stroke | 2022 |
Effect of PCSK9 Monoclonal Antibody Versus Placebo/Ezetimibe on Atrial Fibrillation in Patients at High Cardiovascular Risk: A Meta-Analysis of 26 Randomized Controlled Trials.
Topics: Antibodies, Monoclonal; Anticholesteremic Agents; Atrial Fibrillation; Cardiovascular Diseases; Ezetimibe; Heart Disease Risk Factors; Humans; Proprotein Convertase 9; Randomized Controlled Trials as Topic; Risk Factors | 2023 |
Do we need new lipid-lowering agents in the era of PCSK9 inhibitors? Recent advances.
Topics: Anticholesteremic Agents; Atherosclerosis; Cardiovascular Diseases; Cholesterol, LDL; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; PCSK9 Inhibitors; Proprotein Convertase 9 | 2022 |
Lipid-Modifying Therapies and Stroke Prevention.
Topics: Anticholesteremic Agents; Cardiovascular Diseases; Ezetimibe; Hemorrhagic Stroke; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ischemic Stroke; Lipids; Proprotein Convertase 9; Stroke | 2022 |
[From statin revolution to gene silencing therapy: 50 years of evolution in the treatment of hypercholesterolemia].
Topics: Anticholesteremic Agents; Atherosclerosis; Cardiovascular Diseases; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Gene Silencing; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hyperlipidemias; Proprotein Convertase 9 | 2022 |
Lipid Lowering Therapy: An Era Beyond Statins.
Topics: Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol; Cholesterol, LDL; Dyslipidemias; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2022 |
Extent of Low-density Lipoprotein Cholesterol Reduction and All-cause and Cardiovascular Mortality Benefit: A Systematic Review and Meta-analysis.
Topics: Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol, LDL; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Randomized Controlled Trials as Topic | 2023 |
Under-representation of ethnic and regional minorities in lipid-lowering randomized clinical trials: a systematic review and meta-analysis.
Topics: Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol, LDL; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Stroke | 2023 |
Medical Management of Dyslipidemia for Secondary Stroke Prevention: Narrative Review.
Topics: Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol, LDL; Dyslipidemias; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; PCSK9 Inhibitors; Proprotein Convertase 9; Secondary Prevention; Stroke | 2023 |
Is there benefit to adding ezetimibe to a statin for the secondary prevention of CVD?
Topics: Adult; Anticholesteremic Agents; Cardiovascular Diseases; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Rosuvastatin Calcium; Secondary Prevention | 2023 |
Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention.
Topics: Angiopoietin-Like Protein 3; Anticholesteremic Agents; Cardiovascular Diseases; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertriglyceridemia; Hypolipidemic Agents; Pharmaceutical Preparations; Proprotein Convertase 9; Secondary Prevention | 2023 |
The Effects of Statins, Ezetimibe, PCSK9-Inhibitors, Inclisiran, and Icosapent Ethyl on Platelet Function.
Topics: Anticholesteremic Agents; Atherosclerosis; Cardiovascular Diseases; Cholesterol; Cholesterol, LDL; Eicosapentaenoic Acid; Ezetimibe; Fibrinolytic Agents; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertriglyceridemia; PCSK9 Inhibitors; Proprotein Convertase 9; Triglycerides | 2023 |
Cost-effectiveness of adding ezetimibe and/or PCSK9 inhibitors to high-dose statins for secondary prevention of cardiovascular disease in Chinese adults.
Topics: Adult; Cardiovascular Diseases; Cost-Benefit Analysis; East Asian People; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; PCSK9 Inhibitors; Proprotein Convertase 9; Secondary Prevention | 2023 |
Lipid-lowering therapies for cardiovascular disease prevention and management in primary care: PEER umbrella systematic review of systematic reviews.
Topics: Anticholesteremic Agents; Cardiovascular Diseases; Ezetimibe; Fibric Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Niacin; PCSK9 Inhibitors; Primary Health Care; Proprotein Convertase 9; Systematic Reviews as Topic | 2023 |
Association Between Baseline, Achieved, and Reduction of CRP and Cardiovascular Outcomes After LDL Cholesterol Lowering with Statins or Ezetimibe: A Systematic Review and Meta-Analysis.
Topics: Anticholesteremic Agents; C-Reactive Protein; Cardiovascular Diseases; Cholesterol, LDL; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Myocardial Infarction; Myocardial Revascularization; Stroke; Treatment Outcome | 2019 |
Overall Mortality and LDL Cholesterol Reduction in Secondary Prevention Trials of Cardiovascular Disease.
Topics: Cardiovascular Diseases; Cholesterol, LDL; Ezetimibe; Humans; Lipids; Proprotein Convertase 9; Randomized Controlled Trials as Topic; Secondary Prevention | 2020 |
The efficacy and safety of statin in combination with ezetimibe compared with double-dose statin in patients with high cardiovascular risk: A meta-analysis.
Topics: Cardiovascular Diseases; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2020 |
LDL-cholesterol: The lower the better.
Topics: Anion Exchange Resins; Antibodies, Monoclonal; Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; PCSK9 Inhibitors; Risk | 2019 |
An expert opinion paper on statin adherence and implementation of new lipid-lowering medications by the ESC Working Group on Cardiovascular Pharmacotherapy: Barriers to be overcome.
Topics: Anticholesteremic Agents; Biomarkers; Cardiovascular Diseases; Cholesterol, LDL; Down-Regulation; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Medication Adherence; PCSK9 Inhibitors; Risk Assessment; Risk Factors; Serine Proteinase Inhibitors; Treatment Outcome | 2020 |
[Approach to Patients with Statin Intolerance: Evidence-Based Review].
Topics: Cardiovascular Diseases; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypolipidemic Agents; Meta-Analysis as Topic; Practice Guidelines as Topic; Systematic Reviews as Topic | 2020 |
PCSK9 Inhibitors: From Nature's Lessons to Clinical Utility.
Topics: Animals; Atherosclerosis; Cardiovascular Diseases; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypolipidemic Agents; PCSK9 Inhibitors | 2020 |
Effects and Safety of Statin and Ezetimibe Combination Therapy in Patients with Chronic Kidney Disease: A Systematic Review and Meta-Analysis.
Topics: Adult; Aged; Biomarkers; Cardiovascular Diseases; Cause of Death; Drug Combinations; Dyslipidemias; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney; Lipids; Male; Middle Aged; Patient Safety; Randomized Controlled Trials as Topic; Renal Insufficiency, Chronic; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome | 2020 |
[A decade of progress in the management of dyslipidemia].
Topics: Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol, LDL; Dyslipidemias; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Proprotein Convertase 9 | 2020 |
Quantitative evaluation of statin effectiveness versus intolerance and strategies for management of intolerance.
Topics: Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol; Cholesterol, LDL; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2020 |
Meta-Analysis of Inclisiran for the Treatment of Hypercholesterolemia.
Topics: Aged; Alanine Transaminase; Alkaline Phosphatase; Anticholesteremic Agents; Apolipoproteins B; Aspartate Aminotransferases; Bilirubin; Cardiovascular Diseases; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Creatine Kinase; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Injection Site Reaction; Male; Middle Aged; Myocardial Infarction; Randomized Controlled Trials as Topic; RNA, Small Interfering; Stroke | 2020 |
PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.
Topics: Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Cardiovascular Diseases; Cause of Death; Cholesterol, LDL; Cholinergic Antagonists; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Middle Aged; Myocardial Infarction; PCSK9 Inhibitors; Primary Prevention; Proprotein Convertase 9; Randomized Controlled Trials as Topic; Secondary Prevention; Stroke; Time Factors | 2020 |
Efficacy and safety of lowering LDL cholesterol in older patients: a systematic review and meta-analysis of randomised controlled trials.
Topics: Aged; Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol, LDL; Ezetimibe; Humans; Myocardial Infarction; Randomized Controlled Trials as Topic; Risk Reduction Behavior; Stroke; Treatment Outcome | 2020 |
Lipid-lowering therapy: Guidelines to precision medicine.
Topics: Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol, LDL; Dyslipidemias; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Precision Medicine; Proprotein Convertase 9 | 2021 |
How low is safe? The frontier of very low (<30 mg/dL) LDL cholesterol.
Topics: Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol, LDL; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Proprotein Convertase 9 | 2021 |
Efficacy and safety for the achievement of guideline-recommended lower low-density lipoprotein cholesterol levels: a systematic review and meta-analysis.
Topics: Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol; Cholesterol, LDL; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction | 2022 |
[Elderly benefit from lower LDL-cholesterol].
Topics: Aged; Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol, LDL; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Proprotein Convertase 9 | 2021 |
Statin intolerance: new data and further options for treatment.
Topics: Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol, LDL; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Proprotein Convertase 9 | 2021 |
Meta-analysis of randomized clinical trials comparing PCSK9 monoclonal antibody versus ezetimibe/placebo in patients at high cardiovascular risk.
Topics: Antibodies, Monoclonal; Anticholesteremic Agents; Cardiovascular Diseases; Ezetimibe; Heart Disease Risk Factors; Humans; Proprotein Convertase 9; Randomized Controlled Trials as Topic; Treatment Outcome | 2021 |
Current Perspectives on the Attainment of Lipid Modification Goals Relating to the Use of Statins and Ezetimibe for the Prevention of Cardiovascular Disease in the United Kingdom.
Topics: Benchmarking; Biomarkers; Cardiovascular Diseases; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Primary Prevention; Risk Assessment; Risk Factors; Secondary Prevention; Treatment Outcome; United Kingdom | 2021 |
Effect of More Intensive LDL-C-Lowering Therapy on Long-term Cardiovascular Outcomes in Early-Phase Acute Coronary Syndrome: A Systematic Review and Meta-analysis.
Topics: Acute Coronary Syndrome; Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol, LDL; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Treatment Outcome | 2021 |
Trends in the Utilization of Lipid-Lowering Medications in Australia: An Analysis of National Pharmacy Claims Data.
Topics: Australia; Cardiovascular Diseases; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Pharmaceutical Preparations; Pharmacy; Proprotein Convertases; Subtilisins | 2022 |
PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Cardiovascular Diseases; Cause of Death; Cholesterol, LDL; Cholinergic Antagonists; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Middle Aged; PCSK9 Inhibitors; Primary Prevention; Randomized Controlled Trials as Topic; Secondary Prevention; Time Factors | 2017 |
Advances in the management of dyslipidemia.
Topics: Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol, LDL; Disease Management; Dyslipidemias; Ezetimibe; Fatty Acids, Omega-3; Humans; Proprotein Convertase 9; Risk Factors; Serine Endopeptidases; Triglycerides | 2017 |
Diabetes Update: Prevention and Management of Diabetes Complications.
Topics: Anticholesteremic Agents; Antihypertensive Agents; Cardiovascular Diseases; Depression; Diabetes Complications; Diabetic Nephropathies; Diabetic Neuropathies; Diabetic Retinopathy; Dyslipidemias; Ezetimibe; Gastroparesis; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension | 2017 |
Anti-PCSK9 antibodies for hypercholesterolaemia: Overview of clinical data and implications for primary care.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol, LDL; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; PCSK9 Inhibitors; Primary Health Care; Proprotein Convertase 9 | 2017 |
Incorporation of PCSK9 inhibitors into prevention of atherosclerotic cardiovascular disease.
Topics: Anticholesteremic Agents; Atherosclerosis; Cardiovascular Diseases; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; PCSK9 Inhibitors; Practice Guidelines as Topic; Proprotein Convertase 9 | 2017 |
Effect of statins and non-statin LDL-lowering medications on cardiovascular outcomes in secondary prevention: a meta-analysis of randomized trials.
Topics: Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol, LDL; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; PCSK9 Inhibitors; Randomized Controlled Trials as Topic; Secondary Prevention; Treatment Outcome | 2018 |
The systematic review of randomized controlled trials of PCSK9 antibodies challenges their "efficacy breakthrough" and the "lower, the better" theory.
Topics: Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol, LDL; Ezetimibe; Humans; Hypercholesterolemia; Proprotein Convertase 9; Randomized Controlled Trials as Topic; Treatment Outcome | 2018 |
Effect of ezetimibe on glycemic control: a systematic review and meta-analysis of randomized controlled trials.
Topics: Anticholesteremic Agents; Blood Glucose; Cardiovascular Diseases; Drug Therapy, Combination; Ezetimibe; Glycated Hemoglobin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Randomized Controlled Trials as Topic | 2018 |
A Clinical Guide to Combination Lipid-Lowering Therapy.
Topics: Anticholesteremic Agents; Cardiovascular Diseases; Dyslipidemias; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; PCSK9 Inhibitors | 2018 |
An update on trials of novel lipid-lowering drugs.
Topics: Cardiovascular Diseases; Cholesterol Ester Transfer Proteins; Clinical Trials as Topic; Ezetimibe; Humans; Hypolipidemic Agents; PCSK9 Inhibitors | 2018 |
A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular outcomes.
Topics: Aged; Anticholesteremic Agents; Bayes Theorem; Biomarkers; Cardiovascular Diseases; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Middle Aged; PCSK9 Inhibitors; Randomized Controlled Trials as Topic; Serine Proteinase Inhibitors; Treatment Outcome | 2018 |
Optimizing Statins and Ezetimibe in Guideline-Focused Management.
Topics: Anticholesteremic Agents; Cardiovascular Diseases; Disease Management; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Practice Guidelines as Topic | 2018 |
Association Between Baseline LDL-C Level and Total and Cardiovascular Mortality After LDL-C Lowering: A Systematic Review and Meta-analysis.
Topics: Antibodies, Monoclonal; Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol, LDL; Confounding Factors, Epidemiologic; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Mortality; PCSK9 Inhibitors; Regression Analysis; Risk | 2018 |
Combination Lipid-Lowering Therapies for the Prevention of Recurrent Cardiovascular Events.
Topics: Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; PCSK9 Inhibitors; Recurrence | 2018 |
Efficacy and safety of alirocumab among individuals with diabetes mellitus and atherosclerotic cardiovascular disease in the ODYSSEY phase 3 trials.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Atherosclerosis; Cardiovascular Diseases; Clinical Trials, Phase III as Topic; Diabetes Mellitus; Diabetic Angiopathies; Ezetimibe; Female; Humans; Male; Middle Aged; Randomized Controlled Trials as Topic; Treatment Outcome | 2018 |
Determinants of Achieved LDL Cholesterol and "Non-HDL" Cholesterol in the Management of Dyslipidemias.
Topics: Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials as Topic; Dyslipidemias; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; PCSK9 Inhibitors; Risk Management; Triglycerides | 2018 |
Precision Medicine and Personalized Management of Lipoprotein and Lipid Disorders in Chronic and End-Stage Kidney Disease.
Topics: Anticholesteremic Agents; Cardiovascular Diseases; Dyslipidemias; Ezetimibe; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Kidney Failure, Chronic; Muscular Diseases; Niacin; PCSK9 Inhibitors; Pharmacogenomic Variants; Practice Guidelines as Topic; Precision Medicine; Renal Dialysis; Renal Insufficiency, Chronic | 2018 |
Identifying Patients for Nonstatin Therapy.
Topics: Anticholesteremic Agents; Biomarkers; Cardiovascular Diseases; Cholesterol, LDL; Clinical Decision-Making; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Patient Selection; PCSK9 Inhibitors; Proprotein Convertase 9; Risk Factors; Serine Proteinase Inhibitors; Treatment Outcome | 2018 |
Optimising treatment of hyperlipidaemia: Quantitative evaluation of UK, USA and European guidelines taking account of both LDL cholesterol levels and cardiovascular disease risk.
Topics: Anticholesteremic Agents; Atorvastatin; Cardiology; Cardiovascular Diseases; Cholesterol, LDL; Europe; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hyperlipidemias; Oxazolidinones; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Risk Factors; United Kingdom; United States | 2018 |
Ezetimibe in high-risk, previously treated statin patients: a systematic review and network meta-analysis of lipid efficacy.
Topics: Anticholesteremic Agents; Bayes Theorem; Biomarkers; Cardiovascular Diseases; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Global Health; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Incidence; Risk Factors | 2019 |
Diabetic Dyslipidemia: Epidemiology and Prevention of Cardiovascular Disease and Implications of Newer Therapies.
Topics: Anticholesteremic Agents; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; PCSK9 Inhibitors; Randomized Controlled Trials as Topic; Risk Factors; Risk Reduction Behavior; RNA, Small Interfering | 2018 |
Ezetimibe for the prevention of cardiovascular disease and all-cause mortality events.
Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Cardiovascular Diseases; Cause of Death; Cholesterol; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Middle Aged; Myocardial Infarction; Randomized Controlled Trials as Topic; Simvastatin; Stroke; Triglycerides | 2018 |
[Diagnosis and Treatment of Familial Hypercholesterolemia].
Topics: Apolipoproteins B; Cardiovascular Diseases; DNA Mutational Analysis; Ezetimibe; Genetic Carrier Screening; Genetic Testing; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; PCSK9 Inhibitors; Proprotein Convertase 9; Receptors, LDL | 2018 |
Effects of Lipid Lowering Drugs on Arterial Stiffness: One More Way to Reduce Cardiovascular Risk?
Topics: Biomarkers; Cardiovascular Diseases; Cholesterol, LDL; Dietary Supplements; Down-Regulation; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Fibric Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; PCSK9 Inhibitors; Risk Assessment; Risk Factors; Serine Proteinase Inhibitors; Treatment Outcome; Vascular Stiffness | 2020 |
Evaluating the efficacy and safety of atorvastatin + ezetimibe in a fixed-dose combination for the treatment of hypercholesterolemia.
Topics: Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Cardiovascular Diseases; Drug Combinations; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipids; Risk Factors; Simvastatin | 2019 |
A comparative meta-analysis of the efficacy of statin-ezetimibe co-therapy versus statin monotherapy in reducing cardiovascular and cerebrovascular adverse events in patients with type 2 diabetes mellitus.
Topics: Aged; Cardiovascular Diseases; Case-Control Studies; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Prevalence; Treatment Outcome | 2019 |
An updated review of lipid-modifying therapy.
Topics: Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol, LDL; Disease Management; Dyslipidemias; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Primary Prevention; Proprotein Convertase 9; Randomized Controlled Trials as Topic; Risk Factors; Secondary Prevention; Triglycerides | 2019 |
Maximizing the benefits of cholesterol-lowering drugs.
Topics: Antibodies, Monoclonal; Cardiovascular Diseases; Cholesterol, LDL; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; PCSK9 Inhibitors; Proprotein Convertase 9 | 2019 |
Lipid-lowering agents for concurrent cardiovascular and chronic kidney disease.
Topics: Cardiovascular Diseases; Cholesterol, LDL; Ezetimibe; Fatty Acids, Omega-3; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; PCSK9 Inhibitors; Renal Insufficiency, Chronic | 2019 |
Ezetimibe and bile acid sequestrants: impact on lipoprotein metabolism and beyond.
Topics: Anticholesteremic Agents; Apolipoproteins; Azetidines; Bile Acids and Salts; Cardiovascular Diseases; Cholesterol; Drug Synergism; Drug Therapy, Combination; Ezetimibe; Gene Expression Regulation; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Intestinal Absorption; Lipid Metabolism | 2013 |
Serum lipids and prevention of atherosclerotic cardiovascular events in hemodialysis patients.
Topics: Asian People; Atherosclerosis; Azetidines; Cardiovascular Diseases; Cholesterol; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Lipids; Practice Guidelines as Topic; Renal Dialysis; Renal Insufficiency, Chronic | 2014 |
Management of hypercholesterolemia in children.
Topics: Age Factors; Anticholesteremic Agents; Azetidines; Bile Acids and Salts; Cardiovascular Diseases; Child; Cholesterol; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Life Style; Mass Screening; Risk Factors | 2014 |
Toward individualized cholesterol-lowering treatment in end-stage renal disease.
Topics: Azetidines; Cardiovascular Diseases; Cholesterol, Dietary; Cholesterol, LDL; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Intestinal Absorption; Kidney Failure, Chronic; Phytosterols; Polyamines; Randomized Controlled Trials as Topic; Renal Dialysis; Risk Factors; Sevelamer | 2014 |
Combination therapy in dyslipidemia: where are we now?
Topics: Azetidines; Bile Acids and Salts; Cardiovascular Diseases; Cholesterol; Cholesterol, LDL; Clinical Trials as Topic; Dyslipidemias; Ezetimibe; Female; Fibric Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Lipids; Male; Niacin; Patient Compliance; Proprotein Convertase 9; Proprotein Convertases; Serine Endopeptidases; Treatment Outcome | 2014 |
In brief: adding ezetimibe to a statin improves clinical outcomes.
Topics: Anticholesteremic Agents; Azetidines; Cardiovascular Diseases; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Randomized Controlled Trials as Topic; Treatment Outcome | 2014 |
Improving the odds: ezetimibe and cardiovascular disease.
Topics: Animals; Anticholesteremic Agents; Cardiovascular Diseases; Clinical Trials as Topic; Ezetimibe; Humans | 2015 |
Statin intolerance: diagnosis and remedies.
Topics: Animals; Anticholesteremic Agents; Cardiovascular Diseases; Dietary Supplements; Ezetimibe; Fibric Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Myalgia; Oligonucleotides; Randomized Controlled Trials as Topic; Risk Factors | 2015 |
Clinical efficacy and safety of Ezetimibe on major cardiovascular endpoints: systematic review and meta-analysis of randomized controlled trials.
Topics: Aged; Anticholesteremic Agents; Cardiovascular Diseases; Cause of Death; Comorbidity; Drug Therapy, Combination; Ezetimibe; Female; Humans; Male; Middle Aged; Randomized Controlled Trials as Topic; Simvastatin; Treatment Outcome | 2015 |
Dyslipidemia and cardiovascular disease in women.
Topics: Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Contraindications; Dyslipidemias; Estrogen Replacement Therapy; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Menopause; Patient Selection; Practice Guidelines as Topic; Risk Assessment; Risk Factors; Simvastatin; Triglycerides; United States | 2015 |
Effect of Low-Density Lipoprotein Cholesterol Lowering by Ezetimibe/Simvastatin on Outcome Incidence: Overview, Meta-Analyses, and Meta-Regression Analyses of Randomized Trials.
Topics: Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Humans; Hypercholesterolemia; Incidence; Randomized Controlled Trials as Topic; Simvastatin; Treatment Outcome | 2015 |
Safety and efficacy of ezetimibe: A meta-analysis.
Topics: Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol, LDL; Ezetimibe; Female; Global Health; Humans; Incidence; Male; Risk Factors; Survival Rate; Treatment Outcome | 2015 |
[Statin intolerance].
Topics: Anticholesteremic Agents; Cardiovascular Diseases; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Muscular Diseases; Risk Factors | 2015 |
Nonstatin therapies for management of dyslipidemia: a review.
Topics: Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol Ester Transfer Proteins; Cholesterol, LDL; Clofibrate; Disease Management; Dyslipidemias; Ezetimibe; Fatty Acids, Omega-3; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Niacin; Proprotein Convertases; Risk Factors; Saccharomyces cerevisiae Proteins; Triglycerides; United States | 2015 |
Role of Ezetimibe in Lipid-Lowering and Cardiovascular Disease Prevention.
Topics: Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol, LDL; Ezetimibe; Humans; Lipid Metabolism; Risk Factors | 2015 |
Clinical implications of the IMPROVE-IT trial in the light of current and future lipid-lowering treatment options.
Topics: Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol, LDL; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Randomized Controlled Trials as Topic; Simvastatin | 2016 |
The Role of Ezetimibe in the Treatment of Cardiovascular Disease.
Topics: Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol, LDL; Clinical Trials as Topic; Ezetimibe; Humans; Intestinal Absorption | 2016 |
Niemann-Pick C1-Like 1 (NPC1L1) Inhibition and Cardiovascular Diseases.
Topics: Cardiovascular Diseases; Ezetimibe; Humans; Membrane Proteins; Membrane Transport Proteins; Simvastatin | 2016 |
Statin combination therapy and cardiovascular risk reduction.
Topics: Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Primary Prevention; Risk Factors; Secondary Prevention; Simvastatin | 2016 |
Unmet Needs in LDL-C Lowering: When Statins Won't Do!
Topics: Cardiovascular Diseases; Cholesterol, LDL; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Risk Factors; Subtilisin | 2016 |
[Up to date lipid lowering treatment].
Topics: Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; PCSK9 Inhibitors | 2016 |
Cardiovascular Risk Reduction in Patients with Nonalcoholic Fatty Liver Disease: The Potential Role of Ezetimibe.
Topics: Anticholesteremic Agents; Atherosclerosis; Cardiovascular Diseases; Dyslipidemias; Endothelium, Vascular; Ezetimibe; Humans; Inflammation; Insulin Resistance; Intra-Abdominal Fat; Liver; Metabolic Syndrome; Non-alcoholic Fatty Liver Disease; Obesity; Obesity, Abdominal; Risk Reduction Behavior; Thrombophilia | 2016 |
Glycaemic Effects of Non-statin Lipid-Lowering Therapies.
Topics: Anticholesteremic Agents; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Ezetimibe; Fibric Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypolipidemic Agents; Lipid Metabolism; Meta-Analysis as Topic; Niacin; PCSK9 Inhibitors; Randomized Controlled Trials as Topic; Treatment Outcome | 2016 |
Does the addition of ezetimibe to statins reduce cardiovascular risk?
Topics: Anticholesteremic Agents; Cardiovascular Diseases; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Risk Factors | 2016 |
Addition of Ezetimibe to statins for patients at high cardiovascular risk: Systematic review of patient-important outcomes.
Topics: Anticholesteremic Agents; Cardiovascular Diseases; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Patient Outcome Assessment | 2018 |
Treatment of Dyslipidemias to Prevent Cardiovascular Disease in Patients with Type 2 Diabetes.
Topics: Anticholesteremic Agents; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dyslipidemias; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin Resistance; Life Style; Lipoproteins; Practice Guidelines as Topic; Randomized Controlled Trials as Topic | 2017 |
Hypercholesterolemia As a Risk Factor for Cardiovascular Disease: Current Controversial Therapeutic Management.
Topics: Animals; Anticholesteremic Agents; Atherosclerosis; Biological Transport; Cardiovascular Diseases; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Receptors, LDL; Risk Factors | 2016 |
Combination therapy in cholesterol reduction: focus on ezetimibe and statins.
Topics: Anticholesteremic Agents; Azetidines; Cardiovascular Diseases; Cholesterol; Cholesterol, LDL; Dose-Response Relationship, Drug; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Intestinal Absorption; Liver; Practice Guidelines as Topic; Treatment Outcome | 2008 |
[Crosstalk between cholesterol homeostasis and drug metabolism].
Topics: Animals; Anticholesteremic Agents; Atherosclerosis; Azetidines; Bile; Cardiovascular Diseases; Cholesterol; Cholesterol, Dietary; Cytochrome P-450 Enzyme System; Ezetimibe; Feedback, Physiological; Homeostasis; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Liver; Pharmaceutical Preparations; Receptor Cross-Talk; Receptors, Cytoplasmic and Nuclear | 2008 |
[Cardiovascular mortality in kidney transplatation].
Topics: Anticholesteremic Agents; Azetidines; Cardiovascular Diseases; Comorbidity; Coronary Angiography; Diabetes Mellitus; Dyslipidemias; Ezetimibe; Humans; Kidney Diseases; Kidney Transplantation; Myocardial Ischemia; Obesity; Postoperative Complications; Preoperative Care; Prognosis; Risk Factors | 2008 |
Role of ezetimibe in the management of patients with atherosclerosis.
Topics: Anticholesteremic Agents; Atherosclerosis; Azetidines; Cardiovascular Diseases; Cholesterol, LDL; Down-Regulation; Evidence-Based Medicine; Ezetimibe; Humans; Practice Guidelines as Topic; Time Factors; Treatment Outcome | 2009 |
Cost effectiveness of ezetimibe in patients with cardiovascular disease and statin intolerance or contraindications: a Markov model.
Topics: Age Factors; Anticholesteremic Agents; Azetidines; Cardiovascular Diseases; Cholesterol, LDL; Cohort Studies; Contraindications; Cost-Benefit Analysis; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Markov Chains; Middle Aged; Models, Economic; Quality-Adjusted Life Years; United Kingdom | 2008 |
Statin and ezetimibe combination therapy in cardiovascular disease.
Topics: Animals; Anticholesteremic Agents; Azetidines; Cardiovascular Diseases; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Treatment Outcome | 2009 |
The use of lipid-lowering drug therapy in children and adolescents.
Topics: Adolescent; Atherosclerosis; Azetidines; Bile Acids and Salts; Cardiovascular Diseases; Child; Cholesterol; Clofibric Acid; Disease Progression; Dyslipidemias; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Ion Exchange Resins; Niacin; Practice Guidelines as Topic; Treatment Outcome | 2009 |
Impact of ezetimibe on atherosclerosis: is the jury still out?
Topics: Anticholesteremic Agents; Atherosclerosis; Azetidines; Cardiovascular Diseases; Ezetimibe; Humans; Risk Factors | 2009 |
The impact of ezetimibe on endothelial function and other markers of cardiovascular risk.
Topics: Animals; Anticholesteremic Agents; Azetidines; Cardiovascular Diseases; Clinical Trials as Topic; Endothelium, Vascular; Ezetimibe; Humans; Hypercholesterolemia; Risk Factors | 2009 |
Prediction of cardiovascular event risk reduction from lipid changes associated with high potency dyslipidemia therapy.
Topics: Algorithms; Azetidines; Cardiovascular Diseases; Dyslipidemias; Ezetimibe; Female; Humans; Hypolipidemic Agents; Lipids; Lovastatin; Male; Middle Aged; Niacin; Prognosis; Randomized Controlled Trials as Topic; Risk Reduction Behavior; Simvastatin | 2010 |
[Statins and muscular side-effects].
Topics: Age Factors; Aged, 80 and over; Algorithms; Anticholesteremic Agents; Azetidines; Biopsy; Cardiovascular Diseases; Creatine Kinase; Ezetimibe; Female; Humans; Life Style; Male; Muscle, Skeletal; Muscular Diseases; Myositis; Pain; Primary Prevention; Randomized Controlled Trials as Topic; Retrospective Studies; Rhabdomyolysis; Secondary Prevention; Sex Factors; Ubiquinone | 2010 |
Current therapy for patients with sitosterolemia--effect of ezetimibe on plant sterol metabolism.
Topics: Adolescent; Anticholesteremic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 5; ATP-Binding Cassette Transporters; Azetidines; Bile Acids and Salts; Cardiovascular Diseases; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ileum; Ion Exchange Resins; Lipid Metabolism, Inborn Errors; Lipoproteins; Male; Models, Biological; Mutation, Missense; Phytosterols; Sitosterols; Young Adult | 2010 |
Ezetimibe and vascular endothelial function.
Topics: Anticholesteremic Agents; Azetidines; Cardiovascular Diseases; Cholesterol, LDL; Endothelium, Vascular; Ezetimibe; Humans; Hypercholesterolemia | 2011 |
Ezetimibe as a potential treatment for dyslipidemia associated with chronic renal failure and renal transplant.
Topics: Anticholesteremic Agents; Azetidines; Biomarkers; Cardiovascular Diseases; Cholesterol, LDL; Down-Regulation; Drug Therapy, Combination; Dyslipidemias; Evidence-Based Medicine; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Failure, Chronic; Kidney Transplantation; Treatment Outcome | 2010 |
'Trig-onometry': non-high-density lipoprotein cholesterol as a therapeutic target in dyslipidaemia.
Topics: Adult; Azetidines; Cardiovascular Diseases; Cholesterol, HDL; Dyslipidemias; Ezetimibe; Fatty Acids, Omega-3; Female; Fibric Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Male; Middle Aged; Niacin; Practice Guidelines as Topic; Risk Factors; Young Adult | 2011 |
Lowering LDL cholesterol with margarine containing plant stanol/sterol esters: is it still relevant in 2011?
Topics: Anticholesteremic Agents; Azetidines; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus; Ezetimibe; Fibric Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hyperlipoproteinemia Type II; Intestinal Diseases; Lipid Metabolism, Inborn Errors; Margarine; Micronutrients; Niacin; Phytosterols; Sitosterols; Triglycerides | 2011 |
Effects of ezetimibe on atherosclerosis in preclinical models.
Topics: Animals; Anticholesteremic Agents; Apolipoproteins B; Apolipoproteins E; Atherosclerosis; Azetidines; Cardiovascular Diseases; Cholesterol, LDL; Disease Models, Animal; Drug Evaluation, Preclinical; Ezetimibe; Mice; Mice, Knockout; Rabbits; Risk; Simvastatin | 2011 |
The ezetimibe controversy: implications for clinical practice.
Topics: Acute Coronary Syndrome; Anticholesteremic Agents; Azetidines; Cardiovascular Diseases; Cholesterol, LDL; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Neoplasms; Plaque, Atherosclerotic | 2011 |
Dysfunctional HDL: a novel important diagnostic and therapeutic target in cardiovascular disease?
Topics: Animals; Apolipoproteins; Azetidines; Cardiovascular Diseases; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Ezetimibe; Fibric Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Niacin; Peroxidase; Thiazolidinediones | 2012 |
[Lipid therapy in daily routine].
Topics: Aged; Anticholesteremic Agents; Azetidines; Cardiovascular Diseases; Cholesterol, LDL; Coronary Disease; Drug Therapy, Combination; Dyslipidemias; Evidence-Based Medicine; Ezetimibe; Female; General Practice; Germany; Guideline Adherence; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Medication Adherence; Middle Aged; Myocardial Infarction; Practice Patterns, Physicians'; Prospective Studies; Simvastatin | 2012 |
Lipid abnormalities in patients with chronic kidney disease: implications for the pathophysiology of atherosclerosis.
Topics: Animals; Apolipoproteins B; Atherosclerosis; Azetidines; Cardiovascular Diseases; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Failure, Chronic; Lipids; Lipoprotein(a); Liver; Triglycerides | 2013 |
[The best of clinical pharmacology in 2002].
Topics: Anticholesteremic Agents; Antihypertensive Agents; Azetidines; Cardiovascular Diseases; Ezetimibe; Hormone Replacement Therapy; Humans; Hydrazones; Hypercholesterolemia; Losartan; Myocardial Infarction; Natriuretic Agents; Natriuretic Peptide, Brain; Neovascularization, Physiologic; Nicorandil; Pyridazines; Randomized Controlled Trials as Topic; Simendan; Vasodilator Agents | 2003 |
[Cardiovascular risk factor reduction. Cholesterol absorption inhibitors: a new action principle].
Topics: Anticholesteremic Agents; Azetidines; Cardiovascular Diseases; Cholesterol, Dietary; Drug Interactions; Drug Therapy, Combination; Ezetimibe; Humans; Hypercholesterolemia; Intestinal Absorption; Risk Factors | 2003 |
[Hyperlipidemia: therapeutic principles in clinical practice].
Topics: Adult; Anticholesteremic Agents; Azetidines; Cardiovascular Diseases; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Ezetimibe; Humans; Hyperlipidemias; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Insulin Resistance; Nutritional Physiological Phenomena; Practice Guidelines as Topic; Risk Factors; Time Factors; Weight Loss | 2003 |
Combination therapy in the management of complex dyslipidemias.
Topics: Algorithms; Anticholesteremic Agents; Azetidines; Cardiovascular Diseases; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lipoproteins; Niacin | 2004 |
Management of dyslipidemia in women in the post-hormone therapy era.
Topics: Anticholesteremic Agents; Azetidines; Cardiovascular Diseases; Cholesterol, HDL; Clofibric Acid; Dietary Supplements; Disease Management; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Life Style; Niacin; Practice Guidelines as Topic; Triglycerides | 2005 |
Management of hyperlipidemia: new LDL-C targets for persons at high-risk for cardiovascular events.
Topics: Azetidines; Cardiovascular Diseases; Cholesterol, LDL; Cholestyramine Resin; Clofibric Acid; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Life Style; Niacin; Risk Factors | 2006 |
Combination therapy with ezetimibe and simvastatin to achieve aggressive LDL reduction.
Topics: Anticholesteremic Agents; Atorvastatin; Azetidines; C-Reactive Protein; Cardiovascular Diseases; Drug Therapy, Combination; Ezetimibe; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Intestinal Absorption; Lipoproteins, LDL; Phytosterols; Pravastatin; Pyrroles; Simvastatin | 2006 |
[Lowering cholesterol: how low is low enough?].
Topics: Anticholesteremic Agents; Azetidines; Cardiovascular Diseases; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia | 2006 |
Prospects for the development of novel anti-hyperlipidemic drugs.
Topics: Animals; Azetidines; Cardiovascular Diseases; Carrier Proteins; Cholesterol Ester Transfer Proteins; Ezetimibe; Glycoproteins; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Microsomes; Niacin; Sterol O-Acyltransferase | 2006 |
Drug insight: the role of statins in combination with ezetimibe to lower LDL cholesterol.
Topics: Anticholesteremic Agents; Azetidines; Cardiovascular Diseases; Cholesterol, LDL; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipid Metabolism; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Risk Factors | 2006 |
Statins and solid organ transplantation.
Topics: Adolescent; Adult; Anticholesteremic Agents; Azetidines; Cardiovascular Diseases; Child; Clinical Trials as Topic; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Heart Transplantation; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunosuppressive Agents; Kidney Transplantation; Liver Transplantation; Organ Transplantation; Risk Factors | 2006 |
Optimal lipid modification: the rationale for combination therapy.
Topics: Anticholesteremic Agents; Azetidines; Cardiovascular Diseases; Cholesterol, LDL; Clinical Trials as Topic; Clofibric Acid; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Niacin; Patient Compliance; Patient Selection; Practice Guidelines as Topic; Research Design; Treatment Outcome | 2005 |
Is atorvastatin superior to other statins? Analysis of the clinical trials with atorvastatin having cardiovascular endpoints.
Topics: Amlodipine; Anticholesteremic Agents; Atorvastatin; Azetidines; Cardiovascular Diseases; Clinical Trials as Topic; Clofibric Acid; Ezetimibe; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Heptanoic Acids; Humans; Indoles; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2006 |
New advances in lipid-modifying therapies for reducing cardiovascular risk.
Topics: Acetamides; Acetates; Azetidines; Cardiovascular Diseases; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Niacin; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Sulfonic Acids | 2002 |
49 trial(s) available for ezetimibe and Cardiovascular Diseases
| Article | Year |
|---|---|
Long-term efficacy and safety of moderate-intensity statin with ezetimibe combination therapy versus high-intensity statin monotherapy in patients with atherosclerotic cardiovascular disease (RACING): a randomised, open-label, non-inferiority trial.
Topics: Anticholesteremic Agents; Atherosclerosis; Cardiovascular Diseases; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Rosuvastatin Calcium; Treatment Outcome | 2022 |
Potential Cardiovascular Events Avoided with Bempedoic Acid Plus Ezetimibe Fixed-Dose Combination Compared with Ezetimibe Alone in Patients with Atherosclerotic Cardiovascular Disease Taking Maximally Tolerated Statins.
Topics: Anticholesteremic Agents; Atherosclerosis; Azetidines; Cardiovascular Diseases; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Quality of Life; Treatment Outcome | 2023 |
Small Interfering RNA to Reduce Lipoprotein(a) in Cardiovascular Disease.
Topics: Anticholesteremic Agents; Atherosclerosis; Cardiovascular Diseases; Double-Blind Method; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipoprotein(a); Liver; PCSK9 Inhibitors; RNA, Small Interfering | 2022 |
Moderate-intensity statin with ezetimibe vs. high-intensity statin in patients with diabetes and atherosclerotic cardiovascular disease in the RACING trial.
Topics: Anticholesteremic Agents; Atherosclerosis; Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Treatment Outcome | 2023 |
Effect of rosuvastatin 20 mg versus rosuvastatin 5 mg plus ezetimibe on statin side-effects in elderly patients with atherosclerotic cardiovascular disease: Rationale and design of a randomized, controlled SaveSAMS trial.
Topics: Aged; Anticholesteremic Agents; Atherosclerosis; Cardiovascular Diseases; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Rosuvastatin Calcium; Treatment Outcome | 2023 |
Combination Moderate-Intensity Statin and Ezetimibe Therapy for Elderly Patients With Atherosclerosis.
Topics: Aged; Anticholesteremic Agents; Atherosclerosis; Cardiovascular Diseases; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Treatment Outcome | 2023 |
Moderate-Intensity Statin With Ezetimibe Combination Therapy vs High-Intensity Statin Monotherapy in Patients at Very High Risk of Atherosclerotic Cardiovascular Disease: A Post Hoc Analysis From the RACING Randomized Clinical Trial.
Topics: Anticholesteremic Agents; Atherosclerosis; Cardiovascular Diseases; Cholesterol, LDL; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Rosuvastatin Calcium; United States | 2023 |
The Efficacy and Safety of Moderate-Intensity Rosuvastatin with Ezetimibe versus High-Intensity Rosuvastatin in High Atherosclerotic Cardiovascular Disease Risk Patients with Type 2 Diabetes Mellitus: A Randomized, Multicenter, Open, Parallel, Phase 4 Stu
Topics: Anticholesteremic Agents; Atherosclerosis; Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Ezetimibe; Humans; Hypercholesterolemia; Rosuvastatin Calcium | 2023 |
Biomarkers and Clinical Cardiovascular Outcomes With Ezetimibe in the IMPROVE-IT Trial.
Topics: Aged; Anticholesteremic Agents; Biomarkers; Cardiovascular Diseases; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Humans; Male; Middle Aged; Simvastatin; Treatment Outcome | 2019 |
A Comparison of Two LDL Cholesterol Targets after Ischemic Stroke.
Topics: Adult; Aged; Anticholesteremic Agents; Atherosclerosis; Brain Ischemia; Cardiovascular Diseases; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Intention to Treat Analysis; Ischemic Attack, Transient; Kaplan-Meier Estimate; Male; Middle Aged; Stroke | 2020 |
Low-density lipoprotein cholesterol treatment and outcomes in patients with type 2 diabetes and established cardiovascular disease: Insights from TECOS.
Topics: Aged; Atherosclerosis; Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Male; Middle Aged; Myocardial Infarction; Reference Values; Sitagliptin Phosphate; Stroke | 2020 |
Effectiveness and Safety of Novel Nutraceutical Formulation Added to Ezetimibe in Statin-Intolerant Hypercholesterolemic Subjects with Moderate-to-High Cardiovascular Risk.
Topics: Anticholesteremic Agents; Cardiovascular Diseases; Dietary Supplements; Drug Therapy, Combination; Ezetimibe; Heart Disease Risk Factors; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Risk Factors; Treatment Outcome | 2021 |
Lower levels of high-density lipoprotein cholesterol are associated with increased cardiovascular events in patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Cardiovascular Diseases; Cholesterol, HDL; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Prospective Studies; Quinolines; Treatment Outcome | 2020 |
The nonalcoholic fatty liver disease (NAFLD) fibrosis score, cardiovascular risk stratification and a strategy for secondary prevention with ezetimibe.
Topics: Aged; Anticholesteremic Agents; Cardiovascular Diseases; Ezetimibe; Female; Humans; Internationality; Liver Cirrhosis; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Prospective Studies; Risk Factors; Secondary Prevention; Severity of Illness Index | 2018 |
Lower On-Treatment Low-Density Lipoprotein Cholesterol and Major Adverse Cardiovascular Events in Women and Men: Pooled Analysis of 10 ODYSSEY Phase 3 Alirocumab Trials.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Biomarkers; Cardiovascular Diseases; Cholesterol, LDL; Dose-Response Relationship, Drug; Double-Blind Method; Ezetimibe; Female; Humans; Hypercholesterolemia; Incidence; Male; Middle Aged; Sex Distribution; Sex Factors; Treatment Outcome; United Kingdom | 2018 |
Usefulness of Ezetimibe Versus Evolocumab as Add-On Therapy for Secondary Prevention of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus.
Topics: Aged; Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Ezetimibe; Female; Humans; Incidence; Israel; Male; Middle Aged; Risk Factors; Secondary Prevention; Survival Rate; Treatment Outcome | 2019 |
Cost-effectiveness of lipid lowering with statins and ezetimibe in chronic kidney disease.
Topics: Aged; Aged, 80 and over; Cardiovascular Diseases; Cholesterol, LDL; Cost-Benefit Analysis; Drug Therapy, Combination; Ezetimibe; Female; Health Care Costs; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Life Expectancy; Male; Middle Aged; Models, Economic; Quality-Adjusted Life Years; Renal Insufficiency, Chronic; United Kingdom; United States | 2019 |
Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy.
Topics: Aged; Anticholesteremic Agents; Biomarkers; Cardiovascular Diseases; Cholesterol, LDL; Dicarboxylic Acids; Double-Blind Method; Down-Regulation; Drug Combinations; Ezetimibe; Fatty Acids; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Time Factors; Treatment Outcome; United States | 2020 |
Effects of ezetimibe on markers of synthesis and absorption of cholesterol in high-risk patients with elevated C-reactive protein.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; C-Reactive Protein; Cardiovascular Diseases; Cholesterol; Desmosterol; Ezetimibe; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Male; Middle Aged; Phytosterols; Prospective Studies; Pyrroles; Risk Factors; Sitosterols; Statistics, Nonparametric | 2013 |
Renal and vascular protective effects of ezetimibe in chronic kidney disease.
Topics: Aged; Ankle Brachial Index; Anticholesteremic Agents; Atherosclerosis; Azetidines; Cardiovascular Diseases; Carotid Intima-Media Thickness; Cholesterol, LDL; Dyslipidemias; Ezetimibe; Female; Glomerular Filtration Rate; Humans; Male; Middle Aged; Renal Insufficiency, Chronic; Risk Factors | 2014 |
Effects of ezetimibe on endothelial progenitor cells and microparticles in high-risk patients.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; Biomarkers; Blood Platelets; C-Reactive Protein; Cardiovascular Diseases; Cell-Derived Microparticles; Cholesterol, LDL; Drug Interactions; Endothelial Progenitor Cells; Ezetimibe; Heptanoic Acids; Humans; Middle Aged; Pyrroles; Risk | 2014 |
Critical appraisal of the SHARP trial: the results may be dull.
Topics: Cardiovascular Diseases; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Renal Insufficiency, Chronic; United States | 2014 |
Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol, LDL; Double-Blind Method; Drug Administration Schedule; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Injections, Subcutaneous; Male; Maximum Tolerated Dose; Middle Aged; Treatment Outcome | 2015 |
Alirocumab as Add-On to Atorvastatin Versus Other Lipid Treatment Strategies: ODYSSEY OPTIONS I Randomized Trial.
Topics: Aged; Antibodies; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Atorvastatin; Azetidines; Cardiovascular Diseases; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Female; Heptanoic Acids; Humans; Male; Middle Aged; Pyrroles; Treatment Outcome | 2015 |
Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes.
Topics: Acute Coronary Syndrome; Aged; Anticholesteremic Agents; Azetidines; Cardiovascular Diseases; Cholesterol, LDL; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kaplan-Meier Estimate; Male; Middle Aged; Simvastatin; Triglycerides | 2015 |
Achievement of dual low-density lipoprotein cholesterol and high-sensitivity C-reactive protein targets more frequent with the addition of ezetimibe to simvastatin and associated with better outcomes in IMPROVE-IT.
Topics: Acute Coronary Syndrome; Aged; Anticholesteremic Agents; Biomarkers; C-Reactive Protein; Cardiovascular Diseases; Cerebral Revascularization; Cholesterol, LDL; Comorbidity; Creatinine; Double-Blind Method; Drug Monitoring; Drug Therapy, Combination; Electrocardiography; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Myocardial Revascularization; Simvastatin; Treatment Outcome | 2015 |
Effects of lipid-lowering treatment on circulating microparticles in patients with diabetes mellitus and chronic kidney disease.
Topics: Aged; Anticholesteremic Agents; Biomarkers; Cardiovascular Diseases; Cell-Derived Microparticles; Cross-Over Studies; Diabetes Mellitus; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Flow Cytometry; Humans; Male; Middle Aged; P-Selectin; Renal Insufficiency, Chronic; Risk Factors; Simvastatin | 2016 |
Cost-effectiveness of Simvastatin plus Ezetimibe for Cardiovascular Prevention in CKD: Results of the Study of Heart and Renal Protection (SHARP).
Topics: Aged; Anticholesteremic Agents; Cardiovascular Diseases; Cost-Benefit Analysis; Drug Therapy, Combination; Ezetimibe; Female; Humans; Male; Middle Aged; Renal Insufficiency, Chronic; Simvastatin | 2016 |
Efficacy and safety of adding alirocumab to rosuvastatin versus adding ezetimibe or doubling the rosuvastatin dose in high cardiovascular-risk patients: The ODYSSEY OPTIONS II randomized trial.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol, LDL; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Injections, Subcutaneous; Retrospective Studies; Rosuvastatin Calcium; Time Factors; Treatment Outcome | 2016 |
[ACUTE CORONARY SYNDROME AND LIPID-LOWERING THERAPY. DOES THE IMPROVE-IT STUDY MAKE ANY DIFFERENCE?].
Topics: Acute Coronary Syndrome; Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol, LDL; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Prognosis; Simvastatin; Treatment Outcome | 2015 |
Relationship of baseline HDL subclasses, small dense LDL and LDL triglyceride to cardiovascular events in the AIM-HIGH clinical trial.
Topics: Aged; Anticholesteremic Agents; Cardiovascular Diseases; Cardiovascular System; Cholesterol, HDL; Cohort Studies; Coronary Artery Disease; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins, HDL; Lipoproteins, LDL; Male; Middle Aged; Myocardial Infarction; Niacin; Proportional Hazards Models; Simvastatin; Treatment Outcome; Triglycerides | 2016 |
Effect of omega-3 fatty acid supplementation on arterial elasticity in patients with familial hypercholesterolaemia on statin therapy.
Topics: Apolipoprotein B-100; Arterial Pressure; Biomarkers; Cardiovascular Diseases; Cross-Over Studies; Dietary Supplements; Docosahexaenoic Acids; Drug Combinations; Eicosapentaenoic Acid; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Male; Middle Aged; Time Factors; Treatment Outcome; Triglycerides; Vascular Stiffness; Western Australia | 2016 |
Reductions in Atherogenic Lipids and Major Cardiovascular Events: A Pooled Analysis of 10 ODYSSEY Trials Comparing Alirocumab With Control.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Apolipoprotein B-100; Body Mass Index; Cardiovascular Diseases; Cholesterol, LDL; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Ezetimibe; Female; Follow-Up Studies; Humans; Lipids; Male; Middle Aged; Placebo Effect; Prospective Studies; Treatment Outcome | 2016 |
Combination Therapy of Rosuvastatin and Ezetimibe in Patients with High Cardiovascular Risk.
Topics: Aged; Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Risk Factors; Rosuvastatin Calcium; Treatment Outcome; Triglycerides | 2017 |
Evidence for Reverse Causality in the Association Between Blood Pressure and Cardiovascular Risk in Patients With Chronic Kidney Disease.
Topics: Aged; Anticholesteremic Agents; Blood Pressure; Cardiovascular Diseases; Drug Therapy, Combination; Ezetimibe; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney; Male; Middle Aged; Prognosis; Renal Insufficiency, Chronic; Risk Factors; Simvastatin | 2017 |
Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis.
Topics: Adult; Aged; Aged, 80 and over; Alanine Transaminase; Anticholesteremic Agents; Aortic Valve Stenosis; Aspartate Aminotransferases; Azetidines; Cardiovascular Diseases; Cholesterol, LDL; Coronary Artery Bypass; Disease Progression; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Follow-Up Studies; Heart Valve Prosthesis Implantation; Humans; Kaplan-Meier Estimate; Male; Neoplasms; Simvastatin; Treatment Outcome | 2008 |
Safety and efficacy of combined ezetimibe/simvastatin treatment and simvastatin monotherapy in patients with non-alcoholic fatty liver disease.
Topics: Aged; Alanine Transaminase; Anticholesteremic Agents; Aspartate Aminotransferases; Azetidines; Cardiovascular Diseases; Cholesterol; Creatine Kinase; Drug Combinations; Ezetimibe; Ezetimibe, Simvastatin Drug Combination; Fatty Liver; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipids; Male; Metabolic Syndrome; Middle Aged; Retrospective Studies; Risk Factors; Simvastatin; Triglycerides | 2009 |
Incremental cholesterol reduction with ezetimibe/simvastatin, atorvastatin and rosuvastatin in UK General Practice (IN-PRACTICE): randomised controlled trial of achievement of Joint British Societies (JBS-2) cholesterol targets.
Topics: Aged; Analysis of Variance; Anticholesteremic Agents; Atorvastatin; Azetidines; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Fluorobenzenes; General Practice; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Prospective Studies; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Secondary Prevention; Simvastatin; Sulfonamides; Treatment Outcome | 2010 |
Ezetimibe/simvastatin vs simvastatin in coronary heart disease patients with or without diabetes.
Topics: Aged; Anticholesteremic Agents; Azetidines; Cardiovascular Diseases; Cholesterol, LDL; Coronary Disease; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Middle Aged; Risk Factors; Simvastatin; Statistics as Topic | 2010 |
Lipid-lowering effects of ezetimibe for hypercholesterolemic patients with and without type 2 diabetes mellitus.
Topics: Aged; Azetidines; Biomarkers; Body Mass Index; C-Reactive Protein; Cardiovascular Diseases; Cholestanol; Cholesterol; Cholesterol, LDL; Diabetes Mellitus, Type 2; Ezetimibe; Female; Humans; Hypercholesterolemia; Hypolipidemic Agents; Lipids; Male; Middle Aged; Phytosterols; Sitosterols | 2010 |
The role of niacin in raising high-density lipoprotein cholesterol to reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and optimally treated low-density lipoprotein cholesterol Rationale and study design. The Atherothro
Topics: Anticholesteremic Agents; Atherosclerosis; Azetidines; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Ezetimibe; Humans; Hypolipidemic Agents; Metabolic Syndrome; Niacin; Research Design; Simvastatin; Treatment Outcome | 2011 |
The role of niacin in raising high-density lipoprotein cholesterol to reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and optimally treated low-density lipoprotein cholesterol: baseline characteristics of study partici
Topics: Aged; Anticholesteremic Agents; Azetidines; Cardiovascular Diseases; Cholesterol, HDL; Coronary Artery Disease; Delayed-Action Preparations; Drug Therapy, Combination; Endpoint Determination; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Male; Middle Aged; Niacin; Simvastatin; Triglycerides | 2011 |
The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial.
Topics: Adult; Aged; Azetidines; Cardiovascular Diseases; Cholesterol, LDL; Confidence Intervals; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Ezetimibe; Female; Follow-Up Studies; Humans; Hypolipidemic Agents; Kidney Function Tests; Male; Middle Aged; Reference Values; Renal Dialysis; Renal Insufficiency, Chronic; Risk Assessment; Severity of Illness Index; Simvastatin; Survival Analysis; Time Factors; Treatment Outcome | 2011 |
Clinical implications of electrocardiographic left ventricular strain and hypertrophy in asymptomatic patients with aortic stenosis: the Simvastatin and Ezetimibe in Aortic Stenosis study.
Topics: Aged; Aged, 80 and over; Aortic Valve Stenosis; Azetidines; Cardiovascular Diseases; Drug Therapy, Combination; Electrocardiography; Ezetimibe; Female; Follow-Up Studies; Heart Failure; Humans; Hypertrophy, Left Ventricular; Male; Middle Aged; Myocardial Infarction; Prognosis; Simvastatin; Ventricular Dysfunction, Left | 2012 |
Comparative efficacy and safety of fenofibrate/pravastatin plus ezetimibe triple therapy and simvastatin/ezetimibe dual therapy in type 2 diabetic patients with mixed hyperlipidaemia and cardiovascular disease.
Topics: Aged; Azetidines; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; Ezetimibe; Female; Fenofibrate; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Pravastatin; Simvastatin; Treatment Outcome | 2012 |
Ezetimibe/simvastatin 10/40 mg versus atorvastatin 40 mg in high cardiovascular risk patients with primary hypercholesterolemia: a randomized, double-blind, active-controlled, multicenter study.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; C-Reactive Protein; Cardiovascular Diseases; Double-Blind Method; Drug Combinations; Ezetimibe; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Lipids; Male; Middle Aged; Pyrroles; Simvastatin; Treatment Outcome | 2012 |
Effects of statin monotherapy versus statin plus ezetimibe combination on serum uric acid levels.
Topics: Adult; Aged; Anticholesteremic Agents; Azetidines; Cardiovascular Diseases; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin Resistance; Male; Middle Aged; Prospective Studies; Uric Acid | 2013 |
Hypertension in aortic stenosis: implications for left ventricular structure and cardiovascular events.
Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Antihypertensive Agents; Aortic Valve Stenosis; Azetidines; Blood Pressure; Cardiovascular Diseases; Drug Therapy, Combination; Echocardiography; Ezetimibe; Female; Humans; Hypertension; Hypertrophy, Left Ventricular; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Prognosis; Proportional Hazards Models; Prospective Studies; Risk Assessment; Risk Factors; Simvastatin | 2012 |
Efficacy and safety of rosuvastatin 40 mg alone or in combination with ezetimibe in patients at high risk of cardiovascular disease (results from the EXPLORER study).
Topics: Aged; Azetidines; Cardiovascular Diseases; Dose-Response Relationship, Drug; Drug Therapy, Combination; Ezetimibe; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome | 2007 |
161 other study(ies) available for ezetimibe and Cardiovascular Diseases
| Article | Year |
|---|---|
The Projected Impact of Population-Wide Achievement of LDL Cholesterol <70 mg/dL on the Number of Recurrent Events Among US Adults with ASCVD.
Topics: Adult; Anticholesteremic Agents; Atherosclerosis; Cardiovascular Diseases; Cholesterol, LDL; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Nutrition Surveys; United States | 2023 |
Lipid lowering therapy in primary and secondary prevention in Austria: are LDL-C goals achieved? : Results from the DA VINCI study.
Topics: Anticholesteremic Agents; Atherosclerosis; Austria; Cardiovascular Diseases; Cholesterol, LDL; Cross-Sectional Studies; Ezetimibe; Goals; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Proprotein Convertase 9; Secondary Prevention; Treatment Outcome | 2022 |
Impact of demographic characteristics and antihyperglycemic and cardiovascular drugs on the cardiorenal benefits of SGLT2 inhibitors in patients with type 2 diabetes mellitus: A protocol for systematic review and meta-analysis.
Topics: Cardiovascular Agents; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diuretics; Ezetimibe; Heart Failure; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Meta-Analysis as Topic; Socioeconomic Factors; Sodium-Glucose Transporter 2 Inhibitors; Systematic Reviews as Topic | 2021 |
Cost-Effectiveness of Lipid-Lowering Therapies for Cardiovascular Prevention in Germany.
Topics: Cardiovascular Diseases; Cost-Benefit Analysis; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Proprotein Convertase 9; Quality-Adjusted Life Years | 2023 |
Lipoprotein(a) levels from childhood to adulthood: Data in nearly 3,000 children who visited a pediatric lipid clinic.
Topics: Adolescent; Adult; Cardiovascular Diseases; Child; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoprotein(a); Risk Factors; Young Adult | 2022 |
A Paradigm Shift in Dyslipidemia Management in Primary Care: A 12-Month Cohort Study.
Topics: Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol, LDL; Cohort Studies; Diabetes Mellitus; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Primary Health Care; Rosuvastatin Calcium | 2022 |
Comparison of Evolocumab and Ezetimibe, Both Combined with Statin Therapy, for Patients with Recent Acute Coronary Syndrome: A Cost-Effectiveness Analysis from the Chinese Healthcare Perspective.
Topics: Acute Coronary Syndrome; Anticholesteremic Agents; Atherosclerosis; Cardiovascular Diseases; Cholesterol, LDL; Cost-Benefit Analysis; Cost-Effectiveness Analysis; Ezetimibe; Homozygous Familial Hypercholesterolemia; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Proprotein Convertase 9 | 2023 |
BMJ Rapid Recommendations on use of proprotein convertase subtilisin/kexin 9 inhibitors and ezetimibe to reduce cardiovascular risk.
Topics: Anticholesteremic Agents; Cardiovascular Diseases; Ezetimibe; Heart Disease Risk Factors; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Proprotein Convertase 9; Proprotein Convertases; Risk Factors; Subtilisins | 2022 |
[Study protocol:
Topics: Aged; Cardiovascular Diseases; Cohort Studies; Deprescriptions; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Observational Studies as Topic; Outcome Assessment, Health Care; Primary Prevention; Spain | 2022 |
The absolute cardiovascular benefits of PCSK9 inhibitors and ezetimibe added to maximally tolerated statin therapy depend on individual baseline cardiovascular risk.
Topics: Anticholesteremic Agents; Cardiovascular Diseases; Drug Therapy, Combination; Ezetimibe; Heart Disease Risk Factors; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; PCSK9 Inhibitors; Proprotein Convertase 9; Risk Factors | 2022 |
Cost-Effectiveness of Icosapent Ethyl, Evolocumab, Alirocumab, Ezetimibe, or Fenofibrate in Combination with Statins Compared to Statin Monotherapy.
Topics: Antibodies, Monoclonal, Humanized; Cardiovascular Diseases; Cost-Benefit Analysis; Dyslipidemias; Eicosapentaenoic Acid; Ezetimibe; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Proprotein Convertase 9; Quality-Adjusted Life Years; State Medicine | 2022 |
Recommendations for use of ezetimibe and/or PCSK9 inhibitors in patients with elevated LDL-C.
Topics: Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol, LDL; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; PCSK9 Inhibitors; Proprotein Convertase 9 | 2022 |
2022 ACC Expert Consensus Decision Pathway on the Role of Nonstatin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Solution Set Oversight Committee.
Topics: Anticholesteremic Agents; Cardiology; Cardiovascular Diseases; Cholesterol, LDL; Consensus; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; United States | 2022 |
Combination of ezetimibe and moderate-intensity statin for patients with atherosclerotic cardiovascular disease: a paradigm shift in lipid management landscape.
Topics: Anticholesteremic Agents; Atherosclerosis; Cardiovascular Diseases; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Treatment Outcome | 2022 |
Use of lipid-lowering therapies in patients with chronic kidney disease and atherosclerotic cardiovascular disease: 2-year results from Getting to an imprOved Understanding of Low-Density lipoprotein cholesterol and dyslipidemia management (GOULD).
Topics: Anticholesteremic Agents; Atherosclerosis; Cardiovascular Diseases; Cholesterol; Cholesterol, LDL; Dyslipidemias; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Renal Insufficiency, Chronic | 2022 |
Patients With High Cardiovascular Risk as Candidates to Bempedoic Acid, After Treatment With Statins, Ezetimibe and PCSK9 Inhibitors: An Estimation and Cost-Effectiveness Analysis.
Topics: Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol, LDL; Cost-Effectiveness Analysis; Ezetimibe; Heart Disease Risk Factors; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; PCSK9 Inhibitors; Proprotein Convertase 9; Retrospective Studies; Risk Factors | 2023 |
Simulation study on LDL cholesterol target attainment, treatment costs, and ASCVD events with bempedoic acid in patients at high and very-high cardiovascular risk.
Topics: Anticholesteremic Agents; Atherosclerosis; Cardiovascular Diseases; Cholesterol, LDL; Ezetimibe; Health Care Costs; Heart Disease Risk Factors; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; PCSK9 Inhibitors; Risk Factors | 2022 |
Trends in Lipid-Lowering Prescriptions: Increasing Use of Guideline-Concordant Pharmacotherapies, U.S., 2017‒2022.
Topics: Adult; Atherosclerosis; Cardiovascular Diseases; Cholesterol; Cholesterol, LDL; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; PCSK9 Inhibitors; Prescriptions; Proprotein Convertase 9 | 2023 |
Lipid-lowering treatment among older patients with atherosclerotic cardiovascular disease.
Topics: Aged; Atherosclerosis; Cardiovascular Diseases; Cholesterol, LDL; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; PCSK9 Inhibitors; Proprotein Convertase 9; Retrospective Studies | 2023 |
RACING to judgement: weighing the value of pre-specified subgroup analyses.
Topics: Atherosclerosis; Cardiovascular Diseases; Diabetes Mellitus; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Judgment | 2023 |
Achievement Rates for Low-Density Lipoprotein Cholesterol Goals in Patients at High Risk of Atherosclerotic Cardiovascular Disease in a Real-World Setting in Japan.
Topics: Anticholesteremic Agents; Atherosclerosis; Cardiovascular Diseases; Cholesterol, LDL; Ezetimibe; Goals; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Japan; Treatment Outcome | 2023 |
LDL cholesterol targets rarely achieved in familial hypercholesterolemia patients: A sex and gender-specific analysis.
Topics: Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol, LDL; Cross-Sectional Studies; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Male; Middle Aged; Proprotein Convertase 9; Retrospective Studies; Treatment Outcome | 2023 |
Optimizing lipid management-impact of the COVID 19 pandemic upon cardiovascular risk in England.
Topics: Cardiovascular Diseases; Cholesterol; Communicable Disease Control; COVID-19; Ezetimibe; Heart Disease Risk Factors; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pandemics; Risk Factors; State Medicine | 2023 |
Trends and outcome of statin therapy in dialysis patients with atherosclerotic cardiovascular diseases: A population-based cohort study.
Topics: Adult; Atherosclerosis; Cardiovascular Diseases; Cohort Studies; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Renal Dialysis; Retrospective Studies | 2023 |
Guideline-Directed Low-Density Lipoprotein Cholesterol Management After Acute Ischemic Stroke: Findings from a National Health Care Service.
Topics: Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol, LDL; Coronary Artery Disease; Delivery of Health Care; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Ischemic Stroke; Stroke | 2023 |
Gaps in Guideline-Based Lipid-Lowering Therapy for Secondary Prevention in the United States: A Retrospective Cohort Study of 322 153 Patients.
Topics: Aged; Cardiovascular Diseases; Child, Preschool; Cholesterol, LDL; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Retrospective Studies; Secondary Prevention; United States | 2023 |
[Hypercholesterolemia and cardiovascular risk].
Topics: Anticholesteremic Agents; Atherosclerosis; Cardiovascular Diseases; Cholesterol, LDL; Ezetimibe; Heart Disease Risk Factors; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hyperlipidemias; Proprotein Convertase 9; Risk Factors | 2023 |
Statin, Ezetimibe, or Fibrate Initiation and Subsequent Use for the Primary and Secondary Prevention of Cardiovascular Diseases among Japanese Patients Aged ≥55 Years: A Nationwide Cohort Study.
Topics: Cardiovascular Diseases; Cohort Studies; Dyslipidemias; East Asian People; Ezetimibe; Female; Fibric Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Retrospective Studies; Secondary Prevention | 2023 |
Proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors.
Topics: Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Atherosclerosis; Cardiovascular Diseases; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; PCSK9 Inhibitors | 2019 |
A large Italian cohort on proprotein convertase subtilisin/kexin type 9 inhibitors.
Topics: Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Cardiovascular Diseases; Ezetimibe; Female; Humans; Italy; Male; Middle Aged; PCSK9 Inhibitors; Retrospective Studies; Secondary Prevention; Subtilisins | 2020 |
PCSK9 Inhibitors' New Users: Analysis of Prescription Patterns and Patients' Characteristics from an Italian Real-world Study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Cardiovascular Diseases; Cholesterol, LDL; Drug Prescriptions; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; PCSK9 Inhibitors; Secondary Prevention | 2020 |
[Ezetimibe as a treatment for dyslipidaemia in CKD].
Topics: Cardiovascular Diseases; Cholesterol, LDL; Dyslipidemias; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Renal Insufficiency, Chronic | 2019 |
Impact of Lipid Monitoring on Treatment Intensification of Cholesterol Lowering Therapies (from the Veterans Affairs Healthcare System).
Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Atherosclerosis; Cardiovascular Diseases; Cholesterol, LDL; Ezetimibe; Female; Guideline Adherence; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipids; Male; Middle Aged; Monitoring, Physiologic; Odds Ratio; Treatment Outcome; United States; Veterans Health Services | 2020 |
Low Density Lipoprotein Cholesterol-Lowering Strategies and Population Health: Time to Move to a Cumulative Exposure Model.
Topics: Asymptomatic Diseases; Cardiovascular Diseases; Cholesterol, LDL; Drug Administration Schedule; Ezetimibe; Genetic Therapy; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Medication Adherence; Models, Biological; PCSK9 Inhibitors; Population Health; Proprotein Convertase 9; Risk; Risk Reduction Behavior; RNA, Small Interfering; Tablets; Vaccination | 2020 |
Notes on the new “Recommendations for the treatment of dyslipidemia. Influencing of lipids to reduce cardiovascular risk”.
Topics: Anticholesteremic Agents; Cardiovascular Diseases; Dyslipidemias; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Proprotein Convertase 9; Risk Factors | 2020 |
Cost-Effectiveness Analysis of Ezetimibe as the Add-on Treatment to Moderate-Dose Rosuvastatin versus High-Dose Rosuvastatin in the Secondary Prevention of Cardiovascular Diseases in China: A Markov Model Analysis.
Topics: Anticholesteremic Agents; Cardiovascular Diseases; China; Cost-Benefit Analysis; Dose-Response Relationship, Drug; Drug Therapy, Combination; Ezetimibe; Humans; Markov Chains; Monte Carlo Method; Quality-Adjusted Life Years; Rosuvastatin Calcium; Secondary Prevention | 2020 |
Letter by Weingärtner et al Regarding Article, "Ezetimibe Lipid-Lowering Trial on Prevention of Atherosclerotic Cardiovascular Disease in 75 or Older (EWTOPIA 75): A Randomized, Controlled Trial".
Topics: Anticholesteremic Agents; Atherosclerosis; Cardiovascular Diseases; Ezetimibe; Humans; Lipids | 2020 |
Response by Kuwabara et al to Letter Regarding Article, "Ezetimibe Lipid-Lowering Trial on Prevention of Atherosclerotic Cardiovascular Disease in 75 or Older (EWTOPIA 75): A Randomized Controlled Trial".
Topics: Anticholesteremic Agents; Atherosclerosis; Cardiovascular Diseases; Ezetimibe; Humans; Lipids | 2020 |
Statins and All-Cause Mortality in Patients Undergoing Hemodialysis.
Topics: Adult; Aged; Cardiovascular Diseases; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Failure, Chronic; Male; Middle Aged; Propensity Score; Renal Dialysis; Retrospective Studies; Survival Rate | 2020 |
Patient Characteristics and Treatment Patterns among Medicare Beneficiaries Initiating PCSK9 Inhibitor Therapy.
Topics: Age Factors; Aged; Aged, 80 and over; Anticholesteremic Agents; Cardiovascular Diseases; Comorbidity; Cross-Sectional Studies; Drug Therapy, Combination; Ezetimibe; Female; Health Expenditures; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Insurance Claim Review; Male; Medicare; PCSK9 Inhibitors; Sex Factors; Sociodemographic Factors; United States | 2021 |
Statins plus ezetimibe in the era of proprotein convertase subtilisin/ kexin type 9 inhibitors.
Topics: Anticholesteremic Agents; Cardiovascular Diseases; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Proprotein Convertase 9; Subtilisins | 2020 |
[Combined Lipid-Lowering Therapy in Elderly and Senile Patients].
Topics: Aged; Anticholesteremic Agents; Cardiovascular Diseases; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Secondary Prevention | 2020 |
Similarities and differences between European and American guidelines on the management of blood lipids to reduce cardiovascular risk.
Topics: Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus; Europe; Ezetimibe; Heart Disease Risk Factors; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertriglyceridemia; PCSK9 Inhibitors; Practice Guidelines as Topic; Primary Prevention; Renal Insufficiency, Chronic; United States | 2020 |
Guideline recommendations, clinical trial data, and new and emerging therapies.
Topics: Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol, LDL; Clinical Trials as Topic; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Proprotein Convertase 9 | 2021 |
2021 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in Adults.
Topics: Adult; Apolipoproteins B; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Dietary Supplements; Dyslipidemias; Eicosapentaenoic Acid; Ezetimibe; Female; Health Behavior; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; PCSK9 Inhibitors; Pregnancy; Pregnancy Complications; Primary Prevention; Risk Assessment; Secondary Prevention | 2021 |
Improving statin treatment strategies to reduce LDL-cholesterol: factors associated with targets' attainment in subjects with and without type 2 diabetes.
Topics: Aged; Aged, 80 and over; Biomarkers; Cardiovascular Diseases; Cholesterol, LDL; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Down-Regulation; Dyslipidemias; Ezetimibe; Female; Heart Disease Risk Factors; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Italy; Male; Medication Adherence; Middle Aged; Primary Prevention; Retrospective Studies; Risk Assessment; Secondary Prevention; Time Factors; Treatment Outcome | 2021 |
Novel Lipid-Lowering Therapies to Reduce Cardiovascular Risk.
Topics: Cardiovascular Diseases; Dicarboxylic Acids; Eicosapentaenoic Acid; Ezetimibe; Fatty Acids; Heart Disease Risk Factors; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; PCSK9 Inhibitors; RNA, Small Interfering | 2021 |
Re: Fei Y, Guyatt GH, Alexander PE, et al. Addition of ezetimibe to statins for patients at high cardiovascular risk: Systematic review of patient-important outcomes. J Eval Clin Pract.
Topics: Cardiovascular Diseases; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Risk Factors | 2018 |
Modelling the cost-effectiveness of PCSK9 inhibitors vs. ezetimibe through LDL-C reductions in a Norwegian setting.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol, LDL; Cost-Benefit Analysis; Ezetimibe; Female; Humans; Hypercholesterolemia; Incidence; Middle Aged; Norway; PCSK9 Inhibitors; Risk Factors; Secondary Prevention | 2018 |
Reducing CV risk in diabetes: An ADA update.
Topics: Antihypertensive Agents; Aspirin; Benzhydryl Compounds; Cardiovascular Diseases; Contraindications; Creatinine; Diabetes Complications; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Drug Chronotherapy; Ezetimibe; Fenofibrate; Glucosides; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypertension; Hypoglycemic Agents; Hypolipidemic Agents; Life Style; Liraglutide; Metformin; Niacin; PCSK9 Inhibitors; Platelet Aggregation Inhibitors; Risk Reduction Behavior; Thiazolidinediones | 2017 |
PCSK9 inhibitors- A new age in lipid management?
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Cardiomyopathies; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Lipoproteins, LDL; PCSK9 Inhibitors; Proprotein Convertase 9; Randomized Controlled Trials as Topic; Risk; Serine Proteinase Inhibitors | 2017 |
Reduction of LDL-C-related residual cardiovascular risk with ezetimibe: are mechanistic considerations warranted in practice?
Topics: Acute Coronary Syndrome; Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol, LDL; Dyslipidemias; Ezetimibe; Humans; Prospective Studies; Quinolines; Risk Factors | 2017 |
How many familial hypercholesterolemia patients are eligible for PCSK9 inhibition?
Topics: Adult; Aged; Anticholesteremic Agents; Cardiovascular Diseases; Eligibility Determination; Ezetimibe; Female; Guideline Adherence; Health Services Accessibility; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Male; Middle Aged; PCSK9 Inhibitors; Practice Guidelines as Topic; Proprotein Convertase 9; Registries; Risk Assessment; Risk Factors; Serine Proteinase Inhibitors; Spain; Time Factors; Treatment Outcome | 2017 |
Effectiveness of adherence to lipid lowering therapy on LDL-cholesterol in patients with very high cardiovascular risk: A real-world evidence study in primary care.
Topics: Aged; Cardiovascular Diseases; Cholesterol, LDL; Drug Administration Schedule; Ezetimibe; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Italy; Longitudinal Studies; Male; Medication Adherence; Middle Aged; Primary Health Care; Probability; Retrospective Studies; Risk Factors; Treatment Outcome | 2017 |
Detection of atherosclerotic cardiovascular disease influences the perceived need for aggressive lipid management.
Topics: Aged; Angina, Unstable; Atherosclerosis; Cardiologists; Cardiology; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Middle Aged; PCSK9 Inhibitors; Practice Patterns, Physicians'; Renal Insufficiency, Chronic; Risk Assessment; Severity of Illness Index; Surveys and Questionnaires | 2017 |
Clinical Features and Gaps in the Management of Probable Familial Hypercholesterolemia and Cardiovascular Disease.
Topics: Adult; Aged; Anticholesteremic Agents; Atherosclerosis; Cardiovascular Diseases; Disease Management; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Male; Middle Aged; Myocardial Revascularization; Risk Factors; Treatment Outcome | 2017 |
Risk assessement and its management: from SCORE to statins, ezetimibe to PCSK inhibitors.
Topics: Cardiovascular Agents; Cardiovascular Diseases; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; PCSK9 Inhibitors; Practice Guidelines as Topic; Risk Assessment | 2017 |
Treatment Patterns, Statin Intolerance, and Subsequent Cardiovascular Events Among Japanese Patients With High Cardiovascular Risk Initiating Statin Therapy.
Topics: Adult; Aged; Atherosclerosis; Cardiovascular Diseases; Cohort Studies; Comorbidity; Diabetes Mellitus, Type 2; Drug Substitution; Drug Tolerance; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Japan; Male; Middle Aged; Practice Patterns, Physicians'; Retrospective Studies | 2018 |
Proprotein Convertase Subtilisin-Kexin Type 9 (PCSK9) Inhibitors and Cardiovascular Risk: Does a Further Analysis of the Fourier Trial Suggest Changes in the Target of Lipid Lowering Therapy?
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Biomarkers; Cardiovascular Diseases; Cholesterol, LDL; Clinical Trials as Topic; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; PCSK9 Inhibitors; Proprotein Convertase 9; Risk Factors; Treatment Outcome | 2018 |
Ranking of the most effective treatments for cardiovascular disease using SUCRA: Is it as sweet as it appears?
Topics: Bayes Theorem; Cardiovascular Diseases; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Network Meta-Analysis; Proprotein Convertase 9 | 2018 |
Treatment pattern of familial hypercholesterolemia in Slovakia: Targets, treatment and obstacles in common practice.
Topics: Adult; Anticholesteremic Agents; Biomarkers; Cardiovascular Diseases; Cholesterol, LDL; Down-Regulation; Drug Therapy, Combination; Ezetimibe; Female; Genetic Predisposition to Disease; Guideline Adherence; Heredity; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Male; Middle Aged; Pedigree; Phenotype; Practice Guidelines as Topic; Practice Patterns, Physicians'; Prevalence; Retrospective Studies; Risk Assessment; Risk Factors; Slovakia; Time Factors; Treatment Outcome | 2018 |
LDL-cholesterol target achievement in patients with heterozygous familial hypercholesterolemia at Groote Schuur Hospital: Minority at target despite large reductions in LDL-C.
Topics: Adult; Anticholesteremic Agents; Biomarkers; Cardiovascular Diseases; Cholesterol, LDL; Down-Regulation; Drug Therapy, Combination; Ezetimibe; Female; Genetic Predisposition to Disease; Heredity; Heterozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Male; Middle Aged; PCSK9 Inhibitors; Pedigree; Phenotype; Prevalence; Proprotein Convertase 9; Retrospective Studies; Risk Assessment; Risk Factors; Serine Proteinase Inhibitors; South Africa; Time Factors; Treatment Outcome | 2018 |
Real-life LDL-C treatment goals achievement in patients with heterozygous familial hypercholesterolemia in the Czech Republic and Slovakia: Results of the PLANET registry.
Topics: Anticholesteremic Agents; Biomarkers; Cardiovascular Diseases; Cholesterol, LDL; Cross-Sectional Studies; Czech Republic; Down-Regulation; Drug Therapy, Combination; Ezetimibe; Female; Genetic Markers; Genetic Predisposition to Disease; Heterozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Male; Middle Aged; Mutation; PCSK9 Inhibitors; Phenotype; Proprotein Convertase 9; Registries; Retrospective Studies; Risk Assessment; Serine Proteinase Inhibitors; Slovakia; Time Factors; Treatment Outcome | 2018 |
Burden of familial heterozygous hypercholesterolemia in Uzbekistan: Time is muscle.
Topics: Adult; Aged; Biomarkers; Cardiovascular Diseases; Case-Control Studies; Cholesterol, LDL; Early Diagnosis; Ezetimibe; Female; Gene Frequency; Genetic Predisposition to Disease; Genetic Testing; Heterozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Male; Middle Aged; Phenotype; Polymorphism, Single Nucleotide; Predictive Value of Tests; Proprotein Convertase 9; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome; Uzbekistan | 2018 |
2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
Topics: American Heart Association; Anticholesteremic Agents; Biomarkers; Cardiology; Cardiovascular Diseases; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Medication Therapy Management; PCSK9 Inhibitors; Risk Assessment; Risk Reduction Behavior; United States | 2019 |
2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
Topics: American Heart Association; Anticholesteremic Agents; Biomarkers; Cardiology; Cardiovascular Diseases; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Medication Therapy Management; PCSK9 Inhibitors; Risk Assessment; Risk Reduction Behavior; United States | 2019 |
Association of a Combined Measure of Adherence and Treatment Intensity With Cardiovascular Outcomes in Patients With Atherosclerosis or Other Cardiovascular Risk Factors Treated With Statins and/or Ezetimibe.
Topics: Aged; Anticholesteremic Agents; Atherosclerosis; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Medication Adherence; Middle Aged; Renal Insufficiency, Chronic; Retrospective Studies; Risk Factors | 2018 |
Simulation of the Impact of Statin Intolerance on the Need for Ezetimibe and/or Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor for Meeting Low-Density Lipoprotein Cholesterol Goals in a Population With Atherosclerotic Cardiovascular Disease.
Topics: Algorithms; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Drug Therapy, Combination; Drug Tolerance; Ezetimibe; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; PCSK9 Inhibitors; Retrospective Studies | 2019 |
Four Cases of Cholesterol Management Informed by the 2018 American Heart Association/American College of Cardiology Multisociety Guideline on the Management of Blood Cholesterol.
Topics: Adult; American Heart Association; Anticholesteremic Agents; Atherosclerosis; Cardiology; Cardiovascular Diseases; Cholesterol, LDL; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Practice Guidelines as Topic; Primary Prevention; Secondary Prevention; United States | 2019 |
2018 American Heart Association/American College of Cardiology/Multisociety Guideline on the Management of Blood Cholesterol-Secondary Prevention.
Topics: American Heart Association; Anticholesteremic Agents; Atherosclerosis; Cardiovascular Diseases; Cholesterol, LDL; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Medication Adherence; Patient Care Planning; PCSK9 Inhibitors; Practice Guidelines as Topic; Risk Reduction Behavior; Secondary Prevention; United States | 2019 |
[Possibilities of clinical use of ezetimibe Otrio (JSC "AKRIKHIN", Russia) in patients with high and very high cardiovascular risk who have not reached the target values of lipid metabolism. Conclusion of the Board of experts].
Topics: Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipid Metabolism; Risk Factors; Russia | 2019 |
The cost-effectiveness of lipid lowering for primary cardiovascular prevention in chronic kidney disease: moving beyond statins.
Topics: Cardiovascular Diseases; Cost-Benefit Analysis; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Renal Insufficiency, Chronic | 2019 |
Cost-Effectiveness Analysis of Non-Statin Lipid-Modifying Agents for Secondary Cardiovascular Disease Prevention Among Statin-Treated Patients in Thailand.
Topics: Anticholesteremic Agents; Cardiovascular Diseases; Cost-Benefit Analysis; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Markov Chains; Network Meta-Analysis; PCSK9 Inhibitors; Quality-Adjusted Life Years; Secondary Prevention; Thailand | 2019 |
Bempedoic acid and ezetimibe - better together.
Topics: Cardiovascular Diseases; Dicarboxylic Acids; Ezetimibe; Fatty Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia | 2020 |
[Screening for hyperlipidemia in cardiovascular high-risk patients in austrian diabetes ambulances].
Topics: Ambulatory Care; Anticholesteremic Agents; Austria; Azetidines; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Drug Utilization; Ezetimibe; Fibric Acids; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Mass Screening; Risk Factors; Treatment Outcome; Triglycerides | 2012 |
HPS2-THRIVE results: bad for niacin/laropiprant, good for ezetimibe?
Topics: Adaptor Protein Complex 3; Adaptor Protein Complex beta Subunits; Anticholesteremic Agents; Azetidines; Cardiovascular Diseases; Ezetimibe; Humans; Hypolipidemic Agents; Indoles; Niacin; Simvastatin | 2013 |
First-line treatment patterns and lipid target levels attainment in very high cardiovascular risk outpatients.
Topics: Aged; Anticholesteremic Agents; Azetidines; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus; Drug Administration Schedule; Drug Therapy, Combination; Ezetimibe; Female; Greece; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Outpatients; Prospective Studies; Risk Assessment; Treatment Outcome; Urban Population | 2013 |
Second-line treatments for dyslipidemia in patients at risk of cardiovascular disease.
Topics: Aged; Azetidines; Cardiovascular Diseases; Cholesterol, LDL; Cohort Studies; Diabetes Complications; Dose-Response Relationship, Drug; Drug Monitoring; Drug Resistance; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Hospitals, Teaching; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Japan; Male; Middle Aged; Retrospective Studies; Risk Factors | 2014 |
Endoplasmic reticulum stress effector CCAAT/enhancer-binding protein homologous protein (CHOP) regulates chronic kidney disease-induced vascular calcification.
Topics: Animals; Apolipoproteins E; Atherosclerosis; Azetidines; Calcinosis; Cardiovascular Diseases; Case-Control Studies; Drug Therapy, Combination; Endoplasmic Reticulum; Ezetimibe; Humans; Ketocholesterols; Lipids; Male; Mice, Inbred C57BL; Mice, Knockout; Middle Aged; Renal Insufficiency, Chronic; Simvastatin; Transcription Factor CHOP; Vascular Diseases | 2014 |
Inhibition of smooth muscle cell proliferation by ezetimibe via the cyclin D1-MAPK pathway.
Topics: Animals; Anticholesteremic Agents; Azetidines; Cardiovascular Diseases; Cell Cycle Checkpoints; Cell Movement; Cell Proliferation; Cells, Cultured; Cyclin D1; Depression, Chemical; Ezetimibe; Male; MAP Kinase Signaling System; Molecular Targeted Therapy; Muscle, Smooth, Vascular; Rats, Sprague-Dawley; Up-Regulation | 2014 |
Evaluating cardiovascular event reduction with ezetimibe as an adjunct to simvastatin in 18,144 patients after acute coronary syndromes: final baseline characteristics of the IMPROVE-IT study population.
Topics: Acute Coronary Syndrome; Aged; Anticholesteremic Agents; Azetidines; Cardiovascular Diseases; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Simvastatin | 2014 |
How effective are the ESC/EAS and 2013 ACC/AHA guidelines in treating dyslipidemia? Lessons from a lipid clinic.
Topics: Adult; Aged; Anticholesteremic Agents; Azetidines; Cardiovascular Diseases; Cholesterol, LDL; Drug Therapy, Combination; Dyslipidemias; Europe; Ezetimibe; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Medication Therapy Management; Middle Aged; Practice Guidelines as Topic; Retrospective Studies; Risk Factors; Treatment Outcome; United States | 2015 |
Ezetimibe: rescued by randomization (clinical and mendelian).
Topics: Anticholesteremic Agents; Biomarkers; Cardiovascular Diseases; Cholesterol, LDL; Dyslipidemias; Evidence-Based Medicine; Ezetimibe; Ezetimibe, Simvastatin Drug Combination; Genetic Predisposition to Disease; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Membrane Proteins; Membrane Transport Proteins; Mutation; Phenotype; Polymorphism, Single Nucleotide; Randomized Controlled Trials as Topic; Risk Factors; Treatment Outcome | 2015 |
[Low persistence of simvastatin and ezetimibe fixed combination in the lipid lowering therapy].
Topics: Adult; Aged; Anticholesteremic Agents; Azetidines; Cardiovascular Diseases; Drug Administration Schedule; Drug Combinations; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Kaplan-Meier Estimate; Male; Medication Adherence; Middle Aged; Odds Ratio; Proportional Hazards Models; Retrospective Studies; Risk Factors; Simvastatin; Treatment Outcome | 2015 |
Impact of Switching From High-Efficacy Lipid-Lowering Therapies to Generic Simvastatin on LDL-C Levels and LDL-C Goal Attainment Among High-Risk Primary and Secondary Prevention Populations in the United Kingdom.
Topics: Aged; Aged, 80 and over; Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Cohort Studies; Drugs, Generic; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Retrospective Studies; Risk Factors; Rosuvastatin Calcium; Secondary Prevention; Simvastatin; United Kingdom | 2015 |
Does ezetimibe modify clinical outcomes?
Topics: Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Humans; Treatment Outcome | 2015 |
IMPROVE-IT clinical implications. Should the "high-intensity cholesterol-lowering therapy" strategy replace the "high-intensity statin therapy"?
Topics: Anticholesteremic Agents; Biomarkers; Cardiovascular Diseases; Cholesterol; Clinical Trials as Topic; Down-Regulation; Drug Therapy, Combination; Evidence-Based Medicine; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Practice Guidelines as Topic; Risk Assessment; Risk Factors; Treatment Outcome | 2015 |
Did we IMPROVE-IT: thoughts on LDL targeting post-trial?
Topics: Acute Coronary Syndrome; Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol, LDL; Clinical Trials as Topic; Drug Therapy, Combination; Ezetimibe; Humans; Simvastatin | 2015 |
[LDL cholesterol lowering therapy: no target value but personalised treatment].
Topics: Anticholesteremic Agents; Azetidines; Cardiovascular Diseases; Cholesterol, LDL; Cost-Benefit Analysis; Drug Therapy, Combination; Ezetimibe; Humans; Hypercholesterolemia; Simvastatin | 2015 |
[The surprising (?) results of IMPROVE-IT].
Topics: Anticholesteremic Agents; Azetidines; Biomarkers; Cardiovascular Diseases; Cholesterol, LDL; Clinical Trials as Topic; Congresses as Topic; Ezetimibe; Global Health; Humans; Hypercholesterolemia; Incidence; Italy; Meta-Analysis as Topic; Risk Assessment; Risk Factors; Simvastatin; Treatment Outcome; United States | 2015 |
IMPROVE-IT and genetics reaffirm the causal role of LDL in Cardiovascular Disease.
Topics: Cardiovascular Diseases; Cholesterol, LDL; Drug Approval; Ezetimibe; Genetic Predisposition to Disease; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Membrane Proteins; Membrane Transport Proteins; Mendelian Randomization Analysis; Randomized Controlled Trials as Topic; Research Design | 2015 |
Cholesterol, not just cardiovascular risk, is important in deciding who should receive statin treatment.
Topics: Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Clinical Decision-Making; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Numbers Needed To Treat; Primary Prevention; Risk Assessment; Risk Factors | 2015 |
Cardiovascular protection by ezetimibe and influence on oxidative stress in mice exposed to intermittent hypoxia.
Topics: Animals; Aorta, Thoracic; Cardiotonic Agents; Cardiovascular Diseases; Diet, High-Fat; Ezetimibe; Hypoxia; Male; Mice; Mice, Knockout; Oxidative Stress | 2015 |
Improve-it: Full disclosures?
Topics: Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol, LDL; Disclosure; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Meta-Analysis as Topic; Simvastatin; Treatment Outcome | 2015 |
Has IMPROVE-IT improved cardiovascular outcome?
Topics: Acute Coronary Syndrome; Anticholesteremic Agents; Cardiovascular Diseases; Ezetimibe; Humans; Randomized Controlled Trials as Topic; Treatment Outcome | 2015 |
Intensive LDL lowering therapy for prevention of recurrent cardiovascular events: a word of caution.
Topics: Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Humans; Hypercholesterolemia; PCSK9 Inhibitors; Secondary Prevention; Simvastatin; Treatment Outcome | 2016 |
Might ezetimibe be considered an expensive placebo?
Topics: Cardiovascular Diseases; Clinical Trials as Topic; Ezetimibe; Humans; Hypercholesterolemia; Lipids; Placebo Effect; Treatment Outcome | 2016 |
New Studies Do Not Challenge the American College of Cardiology/American Heart Association Lipid Guidelines.
Topics: American Heart Association; Anticholesteremic Agents; Cardiology; Cardiovascular Diseases; Cholesterol, LDL; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; PCSK9 Inhibitors; Practice Guidelines as Topic; Proprotein Convertase 9; Risk Factors; Societies, Medical; United States | 2016 |
Reply to: Ezetimibe: A real effect?
Topics: Cardiovascular Diseases; Cholesterol, LDL; Ezetimibe; Female; Humans; Male | 2016 |
Efficacy of ezetimibe: A real effect?
Topics: Cardiovascular Diseases; Cholesterol, LDL; Ezetimibe; Female; Humans; Male | 2016 |
[FIXED COMBINATION ATORVASTATIN-EZETIMIBE (ATOZET®)].
Topics: Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Drug Combinations; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Risk Factors | 2016 |
Comparison of Calipers for Matching on the Disease Risk Score.
Topics: Aged; Aged, 80 and over; Alendronate; Anti-Inflammatory Agents, Non-Steroidal; Bone Density Conservation Agents; Cardiovascular Diseases; Cohort Studies; Computer Simulation; Cyclooxygenase 2 Inhibitors; Epidemiologic Methods; Ezetimibe; Female; Gastrointestinal Hemorrhage; Humans; Male; Medicare; Models, Theoretical; Monte Carlo Method; Odds Ratio; Osteoporotic Fractures; Prognosis; Propensity Score; Raloxifene Hydrochloride; Risk Assessment; Simvastatin; United States | 2016 |
Adding Ezetimibe to Simvastatin for the Secondary Prevention of Cardiovascular Disease: Is it Useful?
Topics: Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Humans; Hypercholesterolemia; Secondary Prevention; Simvastatin | 2016 |
Reply: Adding Ezetimibe to Simvastatin for the Secondary Prevention of Cardiovascular Disease: Is it Useful?
Topics: Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Humans; Hypercholesterolemia; Secondary Prevention; Simvastatin | 2016 |
The efficacy of ezetimibe does not seem a credible real effect.
Topics: Anticholesteremic Agents; Cardiovascular Diseases; Ezetimibe; Humans; Meta-Analysis as Topic | 2016 |
A study in high-risk, maximally pretreated patients to determine the potential use of PCSK9 inhibitors at various thresholds of total and LDL cholesterol levels.
Topics: Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol, LDL; Cost-Benefit Analysis; Ezetimibe; Female; Humans; Hypercholesterolemia; Male; PCSK9 Inhibitors; Practice Patterns, Physicians'; Secondary Prevention; United Kingdom | 2017 |
Cost-effectiveness of PCSK9 Inhibitor Therapy in Patients With Heterozygous Familial Hypercholesterolemia or Atherosclerotic Cardiovascular Disease.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Atherosclerosis; Cardiovascular Diseases; Cholesterol, LDL; Cost-Benefit Analysis; Drug Costs; Ezetimibe; Female; Humans; Hyperlipoproteinemia Type II; Male; Middle Aged; Proprotein Convertase 9; Proprotein Convertases; Quality-Adjusted Life Years; Serine Endopeptidases; Uncertainty; United States | 2016 |
A 10-year experience using combined lipid-lowering pharmacotherapy in children and adolescents.
Topics: Adolescent; Anticholesteremic Agents; Argentina; Cardiovascular Diseases; Child; Cholesterol, LDL; Combined Modality Therapy; Diet, Fat-Restricted; Drug Monitoring; Drug Therapy, Combination; Ezetimibe; Female; Follow-Up Studies; Hospitals, Pediatric; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lipoproteins, LDL; Male; Outpatient Clinics, Hospital; Practice Guidelines as Topic; Prospective Studies; Risk Factors; Severity of Illness Index | 2016 |
[Lipids and cerebrovascular disease - New therapeutic options in lowering LDL-cholesterol].
Topics: Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Humans; Hyperlipidemias; Risk Management | 2016 |
Statins, Ezetimibe, and Proprotein Convertase Subtilisin-Kexin Type 9 Inhibitors to Reduce Low-Density Lipoprotein Cholesterol and Cardiovascular Events.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Atherosclerosis; Cardiovascular Diseases; Cholesterol, LDL; Coronary Artery Disease; Dyslipidemias; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; PCSK9 Inhibitors; Practice Guidelines as Topic | 2017 |
Updates on prevention: obesity, ezetimibe, PCSK9, and HIV infection.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Body Mass Index; Cardiovascular Diseases; Cholesterol, LDL; Ezetimibe; HIV Infections; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hyperlipidemia, Familial Combined; Obesity; PCSK9 Inhibitors; Testosterone | 2016 |
Lipid-lowering treatment modifications among patients with hyperlipidemia and a prior cardiovascular event: a US retrospective cohort study.
Topics: Adult; Aged; Cardiovascular Diseases; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Medication Therapy Management; Middle Aged; Outcome and Process Assessment, Health Care; Retrospective Studies; Time Factors; United States | 2017 |
[Cost effectiveness in the Danish health care of ezetemibe co-administration compared to simvastatin].
Topics: Anticholesteremic Agents; Azetidines; Cardiovascular Diseases; Coronary Disease; Cost-Benefit Analysis; Decision Making; Drug Costs; Drug Therapy, Combination; Ezetimibe; Female; Humans; Male; Markov Chains; Middle Aged; Quality-Adjusted Life Years; Risk Factors; Simvastatin; Treatment Outcome | 2008 |
Estimating the health benefits and costs associated with ezetimibe coadministered with statin therapy compared with higher dose statin monotherapy in patients with established cardiovascular disease: results of a Markov model for UK costs using data regis
Topics: Age Factors; Aged; Anticholesteremic Agents; Azetidines; Cardiovascular Diseases; Cost-Benefit Analysis; Dose-Response Relationship, Drug; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipoproteins, LDL; Male; Markov Chains; Middle Aged; Quality of Life; Quality-Adjusted Life Years; Risk Factors; Sex Factors; United Kingdom | 2008 |
Treatment with ezetimibe in kidney transplant recipients with uncontrolled dyslipidemia.
Topics: Adult; Aged; Anticholesteremic Agents; Azetidines; Cardiovascular Diseases; Cholesterol; Creatine Kinase; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunosuppressive Agents; Kidney Transplantation; L-Lactate Dehydrogenase; Lipids; Male; Middle Aged; Prospective Studies; Triglycerides | 2008 |
Should we treat all primary prevention patients with statins?
Topics: Azetidines; Bile Acids and Salts; Cardiovascular Diseases; Cholesterol; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Niacin; Primary Prevention; Triglycerides; Vitamin B Complex | 2009 |
On the road to better dyslipidemia outcomes.
Topics: Azetidines; Cardiovascular Diseases; Clofibric Acid; Dyslipidemias; Ezetimibe; Fish Oils; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Life Style; Lipid Metabolism; Metabolic Syndrome; Niacin; Physical Examination; Risk Assessment; Risk Factors; Vitamin B Complex | 2009 |
Low-density lipoprotein cholesterol reduction and prevention of cardiovascular disease.
Topics: Anticholesteremic Agents; Azetidines; Cardiovascular Diseases; Cholesterol, LDL; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2009 |
What role for [black triangle down] colesevelam in cardiovascular prevention?
Topics: Allylamine; Anticholesteremic Agents; Azetidines; Cardiovascular Diseases; Colesevelam Hydrochloride; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Treatment Outcome | 2009 |
The Zetia challenge: an update.
Topics: Anticholesteremic Agents; Atherosclerosis; Azetidines; Cardiovascular Diseases; Ezetimibe; Humans; Myocardial Infarction | 2009 |
Premature release of data from clinical trials of ezetimibe.
Topics: Adverse Drug Reaction Reporting Systems; Anticholesteremic Agents; Azetidines; Cardiovascular Diseases; Cholesterol, LDL; Databases as Topic; Drug Approval; Drug Therapy, Combination; Ezetimibe; Humans; Hypercholesterolemia; Incidence; Neoplasms; Randomized Controlled Trials as Topic; Registries; Simvastatin; United States | 2009 |
Evaluation of cholesterol lowering treatment of patients with familial hypercholesterolemia: a large cross-sectional study in The Netherlands.
Topics: Adult; Aged; Azetidines; Cardiovascular Diseases; Cholesterol, LDL; Cross-Sectional Studies; Drug Monitoring; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Male; Middle Aged; Netherlands | 2010 |
Fluvastatin/fenofibrate vs. simvastatin/ezetimibe in patients with metabolic syndrome: different effects on LDL-profiles.
Topics: Anticholesteremic Agents; Azetidines; Cardiovascular Diseases; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Fatty Acids, Monounsaturated; Fenofibrate; Fluvastatin; Humans; Hypolipidemic Agents; Indoles; Metabolic Syndrome; Simvastatin | 2010 |
Cost-effectiveness analysis of the use of a high-intensity statin compared to a low-intensity statin in the management of patients with familial hypercholesterolaemia.
Topics: Adult; Age Factors; Aged; Anticholesteremic Agents; Azetidines; Cardiovascular Diseases; Costs and Cost Analysis; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Male; Middle Aged; Models, Theoretical; Risk Factors | 2010 |
Cholesterol drug lowers LDL-C levels but again fails to show clinical benefit.
Topics: Anticholesteremic Agents; Azetidines; Cardiovascular Diseases; Carotid Arteries; Cholesterol, LDL; Clinical Trials as Topic; Drug Approval; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypolipidemic Agents; Niacin; Practice Patterns, Physicians'; Risk Factors; Simvastatin; Treatment Outcome; Ultrasonography; United States; United States Food and Drug Administration | 2010 |
Functional assessment of HDL: Moving beyond static measures for risk assessment.
Topics: Amides; Animals; Anticholesteremic Agents; Azetidines; Cardiovascular Diseases; Cholesterol; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials as Topic; Esters; Ezetimibe; Glucose; Humans; Insulin; Lipase; Lipoproteins, HDL; Niacin; Quinolines; Risk Assessment; Risk Factors; Sulfhydryl Compounds | 2010 |
[Ezetimibe (Ezetrol) in patients with diabetes].
Topics: Anticholesteremic Agents; Azetidines; Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus, Type 2; Ezetimibe; Humans; Intestinal Absorption | 2009 |
[How far the rates of cholesterol have to be lowered in primary prevention?].
Topics: Adult; Anticholesteremic Agents; Azetidines; Cardiovascular Diseases; Cholesterol; Cholesterol, LDL; Controlled Clinical Trials as Topic; Cost-Benefit Analysis; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Primary Prevention; Risk Factors; Simvastatin | 2010 |
The role of ezetimibe in the prevention of cardiovascular disease: where do we stand after ARBITER 6-HALTS.
Topics: Anticholesteremic Agents; Atherosclerosis; Azetidines; Cardiovascular Diseases; Carotid Arteries; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials as Topic; Ezetimibe; Humans; Tunica Intima; Tunica Media | 2010 |
Ezetimibe as a potential treatment for non-alcoholic fatty liver disease: is the intestine a modulator of hepatic insulin sensitivity and hepatic fat accumulation?
Topics: Animals; Anticholesteremic Agents; Azetidines; Cardiovascular Diseases; Ezetimibe; Fatty Liver; Humans; Inflammation; Insulin Resistance; Liver; Membrane Proteins; Membrane Transport Proteins | 2010 |
Effect of ezetimibe monotherapy on lipid metabolism and arterial stiffness assessed by cardio-ankle vascular index in type 2 diabetic patients.
Topics: Ankle; Anticholesteremic Agents; Arteries; Azetidines; Blood Flow Velocity; Cardiovascular Diseases; Cholesterol; Cholesterol, LDL; Diabetes Mellitus, Type 2; Ezetimibe; Female; Humans; Lipid Metabolism; Lipoprotein Lipase; Lipoproteins; Male; Middle Aged; Triglycerides | 2010 |
Don't mess with the DSMB.
Topics: Anticholesteremic Agents; Aortic Valve Stenosis; Azetidines; Cardiovascular Diseases; Clinical Trials Data Monitoring Committees; Diabetes Mellitus, Type 2; Ezetimibe; Humans; Hypoglycemic Agents; Neoplasms; Rosiglitazone; Simvastatin; Thiazolidinediones; United States | 2010 |
Ezetimibe ameliorates cardiovascular complications and hepatic steatosis in obese and type 2 diabetic db/db mice.
Topics: Animals; Anticholesteremic Agents; Azetidines; Blood Pressure; Blood Vessels; Body Composition; Body Weight; Cardiovascular Diseases; Cholesterol; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Ezetimibe; Fatty Liver; Glucose Tolerance Test; Immunohistochemistry; In Vitro Techniques; Insulin Resistance; Liver; Male; Mice; Mice, Inbred C57BL; Myocardium; NADPH Oxidases; Obesity; Superoxides; Triglycerides | 2010 |
HDL and LDL as therapeutic targets for cardiovascular disease prevention: the possible role of niacin.
Topics: Anticholesteremic Agents; Azetidines; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Ezetimibe; Humans; Niacin | 2010 |
[The current debate on lowering LDL cholesterol with ezetimibe].
Topics: Anticholesteremic Agents; Azetidines; Cardiovascular Diseases; Cholesterol, LDL; Ezetimibe; Humans; Hypercholesterolemia | 2010 |
Vascular protective effects of ezetimibe: seeking new therapeutic possibilities of ezetimibe in vascular disease.
Topics: Anticholesteremic Agents; Atherosclerosis; Azetidines; Cardiovascular Diseases; Ezetimibe; Humans | 2011 |
Role of ezetimibe in the prevention of cardiovascular disease: absence of evidence.
Topics: Anticholesteremic Agents; Azetidines; Cardiovascular Diseases; Cholesterol, LDL; Clinical Trials as Topic; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2010 |
Persistent lipid abnormalities in patients treated with statins: Portuguese results of the Dyslipidemia International Study (DYSIS).
Topics: Azetidines; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Dyslipidemias; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Portugal; Simvastatin; Triglycerides | 2011 |
Managing residual risk in patients receiving statin therapy.
Topics: Azetidines; Cardiovascular Diseases; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Simvastatin | 2011 |
Combination therapy with ezetimibe/simvastatin versus statin monotherapy for low-density lipoprotein cholesterol reduction and goal attainment in a real-world clinical setting.
Topics: Anticholesteremic Agents; Azetidines; Cardiovascular Diseases; Cholesterol, LDL; Clinical Trials as Topic; Databases, Factual; Drug Prescriptions; Drug Therapy, Combination; Ezetimibe; Female; Humans; Logistic Models; Male; Middle Aged; Patient Compliance; Retrospective Studies; Risk; Simvastatin; Treatment Outcome | 2011 |
Effect of lipid-lowering treatment on natural history of heterozygous familial hypercholesterolemia in past three decades.
Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Azetidines; Cardiovascular Diseases; Child; Child, Preschool; Cholesterol; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Female; Fluorobenzenes; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Male; Middle Aged; Myocardial Revascularization; Niacin; Ohio; Pyrimidines; Registries; Rosuvastatin Calcium; Sulfonamides; Vitamin B Complex; Young Adult | 2011 |
Clinical characteristics and evaluation of LDL-cholesterol treatment of the Spanish Familial Hypercholesterolemia Longitudinal Cohort Study (SAFEHEART).
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; Cardiovascular Diseases; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Female; Health Status Indicators; Heptanoic Acids; Humans; Hyperlipoproteinemia Type II; Longitudinal Studies; Male; Middle Aged; Pyrroles; Simvastatin; Spain; Young Adult | 2011 |
SHARP: a stab in the right direction in chronic kidney disease.
Topics: Anticholesteremic Agents; Azetidines; Cardiovascular Diseases; Drug Therapy, Combination; Ezetimibe; Female; Humans; Male; Prognosis; Renal Dialysis; Renal Insufficiency, Chronic; Simvastatin; Treatment Outcome | 2011 |
Trial clouds use of niacin with a statin.
Topics: Anticholesteremic Agents; Azetidines; Cardiovascular Diseases; Cholesterol, HDL; Clinical Trials as Topic; Coronary Artery Disease; Delayed-Action Preparations; Drug Therapy, Combination; Endpoint Determination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Niacin; Simvastatin; Treatment Failure | 2011 |
Cardiovascular primary prevention: how high should we set the bar?
Topics: Anticholesteremic Agents; Azetidines; Biomarkers; Cardiovascular Diseases; Cholesterol, LDL; Cost-Benefit Analysis; Drug Industry; Evidence-Based Medicine; Ezetimibe; Fenofibrate; Health Care Costs; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Mass Screening; Neoplasms; Niacin; Primary Prevention; Randomized Controlled Trials as Topic; Simvastatin | 2012 |
[Achievement of therapeutic target in subjects on statin treatment in clinical practice. Results of the STAR (Statins Target Assessment in Real practice) study].
Topics: Aged; Algorithms; Azetidines; Biomarkers; Cardiovascular Diseases; Cerebrovascular Disorders; Cholesterol, LDL; Cohort Studies; Diabetes Complications; Diabetes Mellitus; Ezetimibe; Female; Fluorobenzenes; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Italy; Lovastatin; Male; Medication Adherence; Middle Aged; Pravastatin; Pyrimidines; Retrospective Studies; Risk Assessment; Risk Factors; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome | 2011 |
Into the wardrobe of Narnia: beyond HIV infection a world of cardiovascular risk.
Topics: Acromegaly; Adenoma; Adult; Azetidines; Cardiovascular Diseases; Coinfection; Ezetimibe; Female; Fluorobenzenes; Hepatitis C; HIV Infections; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Magnetic Resonance Imaging; Pituitary Neoplasms; Pyrimidines; Risk Factors; Rosuvastatin Calcium; Sulfonamides | 2012 |
52nd Annual Scientific Session of the American College of Cardiology, Chicago, March 30-April 2, 2003.
Topics: Anticoagulants; Azetidines; Benzylamines; Cardiology; Cardiovascular Diseases; Chicago; Clinical Trials as Topic; Ezetimibe; Fluorobenzenes; Humans; Hyperlipidemias; Hypolipidemic Agents; Pyrimidines; Rosuvastatin Calcium; Sulfonamides | 2003 |
[Ezetimibe (Ezetrol)].
Topics: Anticholesteremic Agents; Azetidines; Cardiovascular Diseases; Cholesterol; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Phytosterols; Treatment Outcome | 2004 |
[Lowering LDL cholesterol frequently does not adhere to guidelines. Also regard intestinal cholesterol source].
Topics: Anticholesteremic Agents; Azetidines; Cardiovascular Diseases; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Guideline Adherence; Humans; Hypercholesterolemia; Intestinal Mucosa; Intestines; Liver; Reference Values; Simvastatin | 2005 |
[Ezetimib and simvastatin. Cooperation at receptors of cholesterol metabolism].
Topics: Adult; Azetidines; Cardiovascular Diseases; Cholesterol, LDL; Drug Synergism; Drug Therapy, Combination; Ezetimibe; Humans; Hypercholesterolemia; Hypolipidemic Agents; Multicenter Studies as Topic; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Simvastatin; Treatment Outcome | 2005 |
[MMW- Drug Prize 2005 for simvastatin/ezetimib (Inegy). LDL goal values are easier to reach now].
Topics: Aged; Anticholesteremic Agents; Awards and Prizes; Azetidines; Cardiovascular Diseases; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Diabetes Mellitus; Drug Combinations; Ezetimibe; Female; Germany; Humans; Male; Periodicals as Topic; Risk Factors; Simvastatin | 2005 |
[Type 2 diabetics are high risk patients. Concerning LDL-cholesterol to approach effectively to two sources].
Topics: Anticholesteremic Agents; Azetidines; C-Reactive Protein; Cardiovascular Diseases; Cholesterol; Cholesterol, LDL; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Ezetimibe; Humans; Risk Factors; Simvastatin; Triglycerides | 2005 |
The clinical effect and tolerability of ezetimibe in high-risk patients managed in a specialty cardiovascular risk reduction clinic.
Topics: Adult; Aged; Aged, 80 and over; Alberta; Ambulatory Care Facilities; Anticholesteremic Agents; Azetidines; Cardiovascular Diseases; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cohort Studies; Ezetimibe; Female; Humans; Hyperlipidemias; Male; Medical Records; Middle Aged; Patient Satisfaction; Retrospective Studies; Triglycerides | 2006 |
[Statin and absorption inhibitor work synergistically. More risk patient reach LDL cholesterol goal value].
Topics: Anticholesteremic Agents; Azetidines; Cardiovascular Diseases; Cholesterol, LDL; Clinical Trials as Topic; Drug Synergism; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Infant, Newborn; Practice Guidelines as Topic; Simvastatin; Treatment Outcome | 2007 |
In brief: Zetia and Vytorin: the ENHANCE study.
Topics: Anticholesteremic Agents; Azetidines; Cardiovascular Diseases; Carotid Artery Diseases; Cholesterol, LDL; Drug Combinations; Ezetimibe; Ezetimibe, Simvastatin Drug Combination; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Randomized Controlled Trials as Topic; Simvastatin; Treatment Outcome | 2008 |
Enhanced LDL-C reduction: lower is better. Does it matter how?
Topics: Anticholesteremic Agents; Azetidines; Cardiovascular Diseases; Cholesterol, LDL; Ezetimibe; Humans; Hypercholesterolemia | 2008 |
Ezetimibe for the treatment of primary (heterozygous-familial and non-familial) hypercholesterolaemia: NICE technology appraisal guidance.
Topics: Adult; Anticholesteremic Agents; Azetidines; Cardiovascular Diseases; Ezetimibe; Female; Heterozygote; Humans; Hypercholesterolemia; Lipids; Male; Practice Guidelines as Topic; Technology Assessment, Biomedical; Treatment Outcome | 2008 |
Commentary on NICE technology appraisal guidance on ezetimibe for the treatment of primary (heterozygous-familial and non-familial) hypercholesterolaemia.
Topics: Adult; Anticholesteremic Agents; Azetidines; Cardiovascular Diseases; Clinical Trials as Topic; Dose-Response Relationship, Drug; Ezetimibe; Female; Heterozygote; Humans; Hypercholesterolemia; Lipids; Male; Practice Guidelines as Topic; Technology Assessment, Biomedical; Treatment Outcome | 2008 |
Predictors of uncontrolled hyperlipidaemia in high-risk ambulatory patients in primary care.
Topics: Aged; Ambulatory Care; Anticholesteremic Agents; Azetidines; Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus; Ezetimibe; Female; Forecasting; Humans; Hypercholesterolemia; Male; Middle Aged; Primary Health Care; Prospective Studies; Risk Assessment; Simvastatin; Treatment Outcome | 2008 |
Promises kept and broken: new pharmaceuticals.
Topics: Anticholesteremic Agents; Azetidines; Cardiovascular Agents; Cardiovascular Diseases; Directories as Topic; Drug Evaluation; Drug Industry; Ezetimibe; Humans; Internet; Ischemic Preconditioning, Myocardial; Nicorandil; Ontario; Product Surveillance, Postmarketing; Pyridines; Thiazepines | 2002 |